COVER PAGE
COVER PAGE - USD ($) $ in Billions | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 27, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 001-33307 | ||
Entity Registrant Name | RadNet, Inc. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 13-3326724 | ||
Entity Address, Address Line One | 1510 Cotner Avenue | ||
Entity Address, City or Town | Los Angeles, | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 90025 | ||
City Area Code | 310 | ||
Local Phone Number | 478-7808 | ||
Title of 12(b) Security | Common Stock, $.0001 par value | ||
Trading Symbol | RDNT | ||
Security Exchange Name | NASDAQ | ||
Entity a Well-known Seasoned Issuer | Yes | ||
Entity a Voluntary Filer | No | ||
Entity's Reporting Status Current | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 2.1 | ||
Entity Common Stock, Shares Outstanding | 68,475,443 | ||
Documents Incorporated by Reference | Portions of the registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this annual report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the close of the registrant’s fiscal year. | ||
Entity Central Index Key | 0000790526 | ||
Amendment Flag | false | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 |
AUDIT INFORMATION
AUDIT INFORMATION | 12 Months Ended |
Dec. 31, 2023 | |
Auditor Information [Abstract] | |
Auditor Name | Ernst & Young LLP |
Auditor Location | Los Angeles, California |
Auditor Firm ID | 42 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 342,570 | $ 127,834 |
Accounts receivable | 163,707 | 166,357 |
Prepaid expenses and other current assets | 47,657 | 54,022 |
Total current assets | 579,276 | 367,184 |
PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS | ||
Property and equipment, net | 604,401 | 565,961 |
Operating lease right-of-use-assets | 596,032 | 603,524 |
Total property, equipment and right-of-use-assets | 1,200,433 | 1,169,485 |
OTHER ASSETS | ||
Goodwill | 679,463 | 677,665 |
Other intangible assets | 90,615 | 106,228 |
Deferred financing costs | 1,643 | 2,280 |
Investment in joint ventures | 92,710 | 57,893 |
Deposits and other | 46,333 | 53,172 |
Total assets | 2,690,473 | 2,433,907 |
CURRENT LIABILITIES | ||
Accounts payable, accrued expenses and other | 342,940 | 369,595 |
Deferred revenue | 4,647 | 4,021 |
Current portion of operating lease liability | 55,981 | 57,607 |
Current portion of notes payable | 17,974 | 12,400 |
Total current liabilities | 437,452 | 466,723 |
LONG-TERM LIABILITIES | ||
Long-term operating lease liability | 605,097 | 604,117 |
Notes payable, net of current portion | 812,068 | 839,344 |
Deferred tax liability, net | 15,776 | 9,256 |
Other non-current liabilities | 6,721 | 23,015 |
Total liabilities | 1,877,114 | 1,942,455 |
RadNet, Inc. stockholders' equity: | ||
Common stock - $.0001 par value, 200,000,000 shares authorized; 67,956,318 and 57,723,125 shares issued and outstanding at December 31, 2023 and 2022 respectively | 7 | 6 |
Additional paid-in-capital | 722,750 | 436,288 |
Accumulated other comprehensive loss | (12,484) | (20,677) |
Accumulated deficit | (79,578) | (82,622) |
Total RadNet, Inc.'s stockholders' equity | 630,695 | 332,995 |
Noncontrolling interests | 182,664 | 158,457 |
Total equity | 813,359 | 491,452 |
Total liabilities and equity | 2,690,473 | 2,433,907 |
Affiliates | ||
CURRENT ASSETS | ||
Due from affiliates | 25,342 | 18,971 |
CURRENT LIABILITIES | ||
Due to affiliates | $ 15,910 | $ 23,100 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Common stock - par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock - authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock - issued (in shares) | 67,956,318 | 67,956,318 |
Common stock - outstanding (in shares) | 57,723,125 | 57,723,125 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
REVENUE | |||
Service fee revenue | $ 1,616,630 | $ 1,430,061 | $ 1,315,077 |
Provider relief funding | 0 | 0 | 9,110 |
OPERATING EXPENSES | |||
Cost of operations, excluding depreciation and amortization | 1,395,239 | 1,264,346 | 1,123,274 |
Gain on contribution of imaging centers into joint venture | (16,808) | 0 | 0 |
Lease abandonment charges | 5,146 | 0 | 19,675 |
Depreciation and amortization | 128,391 | 115,877 | 96,694 |
Loss on sale and disposal of equipment and other | 2,187 | 2,529 | 1,246 |
Severance costs | 3,778 | 946 | 744 |
Total operating expenses | 1,517,933 | 1,383,698 | 1,241,633 |
INCOME FROM OPERATIONS | 98,697 | 46,363 | 82,554 |
OTHER INCOME AND EXPENSES | |||
Interest expense | 64,483 | 50,841 | 48,830 |
Equity in earnings of joint ventures | (6,427) | (10,390) | (10,967) |
Non-cash change in fair value of interest rate swaps | 8,185 | (39,621) | (21,670) |
Loss on extinguishment of debt and related expenses | 0 | 731 | 6,044 |
Other (income) expenses | (6,354) | 1,833 | 1,438 |
Total other expenses | 59,887 | 3,394 | 23,675 |
INCOME BEFORE INCOME TAXES | 38,810 | 42,969 | 58,879 |
Provision for income taxes | (8,473) | (9,361) | (14,560) |
NET INCOME | 30,337 | 33,608 | 44,319 |
Net income attributable to noncontrolling interests | 27,293 | 22,958 | 19,592 |
NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | $ 3,044 | $ 10,650 | $ 24,727 |
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) | $ 0.05 | $ 0.19 | $ 0.47 |
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) | $ 0.05 | $ 0.17 | $ 0.46 |
WEIGHTED AVERAGE SHARES OUTSTANDING | |||
Basic (in shares) | 63,580,059 | 56,293,336 | 52,496,679 |
Diluted (in shares) | 64,658,299 | 57,320,870 | 53,421,033 |
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] | Other (income) expenses | Other (income) expenses | |
Service fee revenue | |||
REVENUE | |||
Service fee revenue | $ 1,463,197 | $ 1,278,016 | $ 1,166,743 |
Revenue under capitation arrangements | |||
REVENUE | |||
Service fee revenue | $ 153,433 | $ 152,045 | $ 148,334 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | |||
NET INCOME | $ 30,337 | $ 33,608 | $ 44,319 |
Currency translation adjustments | 4,617 | (3,943) | (65) |
Change in fair value of cash flow hedge from prior periods reclassified to earnings | 3,576 | 3,687 | 3,695 |
COMPREHENSIVE INCOME | 38,530 | 33,352 | 47,949 |
Less comprehensive income attributable to noncontrolling interests | 27,293 | 22,958 | 19,592 |
COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | $ 11,237 | $ 10,394 | $ 28,357 |
CONSOLIDATED STATEMENT OF EQUIT
CONSOLIDATED STATEMENT OF EQUITY - USD ($) $ in Thousands | Total | Acquisitions And Asset Purchases | DeepHealth, Inc. | Radnet, Inc. Stockholders' Equity | Radnet, Inc. Stockholders' Equity Acquisitions And Asset Purchases | Radnet, Inc. Stockholders' Equity DeepHealth, Inc. | Common Stock | Common Stock Acquisitions And Asset Purchases | Common Stock DeepHealth, Inc. | Additional Paid-in Capital | Additional Paid-in Capital Acquisitions And Asset Purchases | Additional Paid-in Capital DeepHealth, Inc. | Accumulated Other Comprehensive (Loss) Income | Accumulated Deficit | Noncontrolling Interests |
Beginning balance (in shares) at Dec. 31, 2020 | 51,640,537 | ||||||||||||||
Beginning balance at Dec. 31, 2020 | $ 258,303 | $ 165,743 | $ 5 | $ 307,788 | $ (24,051) | $ (117,999) | $ 92,560 | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||
Issuance of stock upon exercise of options (in shares) | 53,960 | ||||||||||||||
Issuance of stock upon exercise of options | 488 | 488 | 488 | ||||||||||||
Shares issued under the equity compensation plan (in shares) | 1,212,758 | 471,162 | |||||||||||||
Stock-based compensation expense | 25,284 | 25,284 | 25,284 | ||||||||||||
Issuance of common stock for acquisitions (in shares) | 82,658 | 91,517 | |||||||||||||
Issuance of common stock for acquisitions | $ 2,498 | $ 2,413 | $ 2,498 | $ 2,413 | $ 2,498 | $ 2,413 | |||||||||
Contribution from noncontrolling partner | 123 | 123 | |||||||||||||
Distributions paid to noncontrolling interests | (2,426) | (2,426) | |||||||||||||
Change in cumulative foreign currency translation adjustment | (65) | (65) | (65) | ||||||||||||
Change in fair value of cash flow hedge from prior periods reclassified to earnings | 3,695 | 3,695 | 3,695 | ||||||||||||
Net income (loss) | 44,319 | 24,727 | 24,727 | 19,592 | |||||||||||
Gain on contribution of assets to majority owned subsidiary | (4) | (4) | (4) | ||||||||||||
Forfeiture of restricted stock (in shares) | (4,365) | ||||||||||||||
Forfeiture of restricted stock | (81) | (81) | (81) | ||||||||||||
Sale to noncontrolling interests, net of taxes | 11,610 | 4,206 | 4,206 | 7,404 | |||||||||||
Ending balance (in shares) at Dec. 31, 2021 | 53,548,227 | ||||||||||||||
Ending balance at Dec. 31, 2021 | 346,157 | 228,904 | $ 5 | 342,592 | (20,421) | (93,272) | 117,253 | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||
Issuance of stock upon exercise of options (in shares) | 25,000 | ||||||||||||||
Issuance of stock upon exercise of options | 295 | 295 | $ 1 | 294 | |||||||||||
Shares issued under the equity compensation plan (in shares) | 725,577 | 204,160 | |||||||||||||
Issuance of common stock to settle DeepHealth contingent consideration (in shares) | 781,577 | ||||||||||||||
Stock-based compensation expense | 23,543 | 23,543 | 23,543 | ||||||||||||
Issuance of common stock for acquisitions (in shares) | 2,465,294 | ||||||||||||||
Issuance of common stock for acquisitions | $ 63,311 | $ 63,311 | $ 63,311 | ||||||||||||
Contribution from noncontrolling partner | 19,139 | 19,139 | |||||||||||||
Distributions paid to noncontrolling interests | (893) | (893) | |||||||||||||
Change in cumulative foreign currency translation adjustment | (3,943) | (3,943) | (3,943) | ||||||||||||
Change in fair value of cash flow hedge from prior periods reclassified to earnings | 3,687 | 3,687 | 3,687 | ||||||||||||
Net income (loss) | 33,608 | 10,650 | 10,650 | 22,958 | |||||||||||
Forfeiture of restricted stock (in shares) | (26,710) | ||||||||||||||
Forfeiture of restricted stock | (75) | (75) | (75) | ||||||||||||
Sale to noncontrolling interests, net of taxes | $ 6,623 | 6,623 | 6,623 | ||||||||||||
Ending balance (in shares) at Dec. 31, 2022 | 57,723,125 | 57,723,125 | |||||||||||||
Ending balance at Dec. 31, 2022 | $ 491,452 | 332,995 | $ 6 | 436,288 | (20,677) | (82,622) | 158,457 | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||
Issuance of stock upon exercise of options (in shares) | 12,723 | 37,909 | 12,424 | ||||||||||||
Issuance of stock upon exercise of options | $ 142 | 142 | 142 | ||||||||||||
Shares issued under the equity compensation plan (in shares) | 1,128,453 | 37,909 | |||||||||||||
Stock-based compensation expense | 26,785 | 26,785 | 26,785 | ||||||||||||
Contribution from noncontrolling partner | 2,885 | 2,885 | |||||||||||||
Distributions paid to noncontrolling interests | (5,972) | (5,972) | |||||||||||||
Change in cumulative foreign currency translation adjustment | 4,617 | 4,617 | 4,617 | ||||||||||||
Change in fair value of cash flow hedge from prior periods reclassified to earnings | 3,576 | 3,576 | 3,576 | ||||||||||||
Net income (loss) | 30,337 | 3,044 | 3,044 | 27,293 | |||||||||||
Issuance of common stock, net of issuance costs (in shares) | 8,711,250 | ||||||||||||||
Issuance of common stock, net of issuance costs | 245,832 | 245,832 | $ 1 | 245,831 | |||||||||||
Issuance of common stock in connection with acquisitions (in shares) | 378,699 | ||||||||||||||
Issuance of common stock in connection with acquisitions | 11,470 | 11,470 | 11,470 | ||||||||||||
Forfeiture of restricted stock (in shares) | (35,542) | ||||||||||||||
Forfeiture of restricted stock | 0 | 0 | |||||||||||||
Sale to noncontrolling interests, net of taxes | 2,236 | 2,236 | 2,236 | ||||||||||||
Other | $ (1) | (2) | 2 | 0 | 1 | ||||||||||
Ending balance (in shares) at Dec. 31, 2023 | 57,723,125 | 67,956,318 | |||||||||||||
Ending balance at Dec. 31, 2023 | $ 813,359 | $ 630,695 | $ 7 | $ 722,750 | $ (12,484) | $ (79,578) | $ 182,664 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
CASH FLOWS FROM OPERATING ACTIVITIES | |||
Net income (loss) | $ 30,337 | $ 33,608 | $ 44,319 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 128,391 | 115,877 | 96,694 |
Amortization of operating lease right-of-use assets | 61,102 | 68,847 | 73,967 |
Lease abandonment charges | 5,146 | 0 | 19,675 |
Equity in earnings of joint ventures, net of dividends | 9,176 | (5,952) | (6,260) |
Amortization and write off of deferred financing costs and loan discount | 2,987 | 2,693 | 3,254 |
Gain on contribution of imaging centers into joint venture | (16,808) | 0 | 0 |
Loss on sale and disposal of equipment and other | 2,187 | 2,529 | 1,246 |
Loss on extinguishment of debt | 0 | 0 | 1,496 |
Loss on impairment | 3,949 | 0 | 0 |
Amortization of cash flow hedge | 3,576 | 3,687 | 3,695 |
Non-cash change in fair value of interest rate swap | 8,185 | (39,621) | (21,670) |
Stock-based compensation | 26,785 | 23,770 | 25,203 |
Change in value of contingent consideration | (3,880) | (325) | 0 |
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | |||
Accounts receivable | 2,650 | (30,078) | (5,890) |
Other current assets | (8,441) | (3,327) | (15,777) |
Other assets | (1,484) | (12,166) | 662 |
Deferred taxes | 6,056 | 13,356 | 19,834 |
Operating lease liability | (54,763) | (68,943) | (72,553) |
Deferred revenue | 626 | (7,316) | (28,319) |
Accounts payable, accrued expenses and other liabilities | 15,086 | 49,778 | 9,915 |
Net cash provided by operating activities | 220,863 | 146,417 | 149,491 |
CASH FLOWS FROM INVESTING ACTIVITIES | |||
Purchase of imaging centers and other operations | (10,918) | (129,961) | (77,691) |
Purchase of property and equipment | (176,600) | (119,451) | (137,874) |
Purchase of intangible assets | 0 | 0 | (5,130) |
Proceeds from sale of equipment | 83 | 3,904 | 625 |
Equity contributions in existing and purchase of interest in joint ventures | (14,035) | (1,441) | (1,441) |
Net cash used in investing activities | (201,470) | (246,949) | (221,511) |
CASH FLOWS FROM FINANCING ACTIVITIES | |||
Payments on term loan debt | (41,063) | (53,750) | (619,529) |
Principal payments on notes and leases payable other than term loan debt | (2,930) | 0 | (3,302) |
Additional deferred finance costs on revolving loan amendment | 0 | 0 | (938) |
Proceeds from debt issuance, net of issuance costs | 0 | 147,996 | 717,307 |
Distributions paid to noncontrolling interests | (5,972) | (893) | (2,426) |
Proceeds from sale of economic interest in majority owned subsidiary | 0 | 0 | 13,073 |
Proceeds from revolving credit facility | 0 | 0 | 128,300 |
Payments on revolving credit facility | 0 | 0 | (128,300) |
Sale of noncontrolling interests | 5,121 | 0 | 0 |
Payments on contingent consideration | (5,495) | 0 | 0 |
Proceeds from issuance of common stock, net of issuance costs | 245,832 | 0 | 0 |
Proceeds from issuance of common stock upon exercise of options | 142 | 294 | 488 |
Net cash provided by financing activities | 195,635 | 93,647 | 104,673 |
EFFECT OF EXCHANGE RATE CHANGES ON CASH | (292) | 113 | (65) |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 214,736 | (6,772) | 32,588 |
CASH AND CASH EQUIVALENTS, beginning of period | 127,834 | 134,606 | 102,018 |
CASH AND CASH EQUIVALENTS, end of period | 342,570 | 127,834 | 134,606 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |||
Cash paid during the period for interest | 64,695 | 39,151 | 29,042 |
Cash paid during the period for income taxes | $ 1,587 | $ 587 | $ 1,950 |
CONSOLIDATED STATEMENTS OF CA_2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands | 12 Months Ended | |||||||||||||
Dec. 12, 2023 | Sep. 20, 2023 | Jul. 07, 2023 | Apr. 13, 2023 | Nov. 01, 2022 | Jan. 20, 2022 | Oct. 22, 2021 | Aug. 24, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Sep. 01, 2023 | Feb. 01, 2023 | Jan. 01, 2021 | |
Equipment acquired and leasehold improvements | $ 67,700 | $ 111,800 | $ 63,900 | |||||||||||
Investment in joint ventures | 92,710 | 57,893 | 42,229 | $ 300 | ||||||||||
Proceeds from sale of equipment | 83 | 3,904 | $ 625 | |||||||||||
Property and equipment, net | $ 604,401 | $ 565,961 | ||||||||||||
Simi Valley Imaging Group, LLC | ||||||||||||||
Investment in joint ventures | 400 | |||||||||||||
Simi Adventist | ||||||||||||||
Investment in joint ventures | $ 100 | |||||||||||||
Unsecured Debt | ||||||||||||||
Debt instrument, face amount | $ 19,800 | |||||||||||||
Santa Monica Imaging Group, LLC | ||||||||||||||
Investment in joint ventures | $ 27,200 | |||||||||||||
Arizona Diagnostics Group | ||||||||||||||
Investment at cost | $ 12,700 | |||||||||||||
Received a dividend from the partnership | 4,500 | |||||||||||||
Fair value of investment | $ 8,300 | |||||||||||||
Aidence | ||||||||||||||
Shares issued (in shares) | 359,002 | 1,141,234 | ||||||||||||
Value of RadNet stock issued in acquisition | $ 6,800 | $ 30,600 | ||||||||||||
Quantib | ||||||||||||||
Shares issued (in shares) | 965,058 | |||||||||||||
Value of RadNet stock issued in acquisition | $ 25,900 | |||||||||||||
Quantib | Stock Holdback | ||||||||||||||
Shares issued (in shares) | 113,303 | |||||||||||||
Value of RadNet stock issued in acquisition | $ 3,500 | |||||||||||||
DRT LLC | ||||||||||||||
Shares issued (in shares) | 15,000,000 | |||||||||||||
Value of shares issued in acquisition | $ 400 | |||||||||||||
Tangent Associates LLC | ||||||||||||||
Shares issued (in shares) | 67,658,000 | |||||||||||||
Value of RadNet stock issued in acquisition | $ 2,000 | |||||||||||||
Heart & Lung Imaging Limited | Stock Holdback | ||||||||||||||
Shares issued (in shares) | 64,569 | 56,600 | ||||||||||||
Value of RadNet stock issued in acquisition | $ 2,300 | $ 1,600 | ||||||||||||
Aidence Holding B.V. milestone consideration | General Holdback | ||||||||||||||
Shares issued (in shares) | 144,227 | |||||||||||||
Value of RadNet stock issued in acquisition | $ 4,000 |
NATURE OF BUSINESS
NATURE OF BUSINESS | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF BUSINESS | NATURE OF BUSINESS We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At December 31, 2023, we operated directly or indirectly through joint ventures with hospitals, 366 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. In addition to our center operations, we have certain other subsidiaries that develop Artificial Intelligence ("AI") products and solutions that are designed to enhance interpretation of radiographic images. Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Artificial Intelligence. For further financial information about these segments, see Note 5, Segment Reporting. In June 2023, we completed a public offering of 8,711,250 shares of our common stock at a price to the public of $29.75 per share. The gross proceeds as a result of this public offering was $259.2 million before underwriting discounts, commissions, and expenses totaling $13.4 million. The consolidated financial statements include the accounts of RadNet, Inc. as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report. Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity. VIEs that we consolidate as the primary beneficiary consist of professional corporations which are owned or controlled by individuals within our senior management and provide professional medical services for centers in Arizona, California, Delaware, Maryland, New Jersey and New York. These VIEs are collectively referred to as the consolidated medical group (the "Group"). RadNet provides non-medical, technical and administrative services to the Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Group has insignificant operating assets and liabilities, and de minimis equity. Substantially all cash flows of the Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Group. The creditors of the Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of the Group. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues. The Group on a combined basis recognized $205.6 million, $189.1 million, and $179.6 million of revenue, net of management services fees to RadNet, for the years ended December 31, 2023, 2022, and 2021, respectively and $205.6 million, $189.1 million, and $179.6 million of operating expenses for the years ended December 31, 2023, 2022, and 2021, respectively. RadNet, Inc. recognized $849.4 million, $786.5 million, and $749.2 million of total billed net service fee revenue for the years ended December 31, 2023, 2022, and 2021, respectively, for management services provided to the Group relating primarily to the technical portion of billed revenue. The cash flows of the Group are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at December 31, 2023 and December 31, 2022, we have included approximately $94.1 million and $110.3 million, respectively, of accounts receivable and approximately $16.7 million and $16.2 million of accounts payable and accrued liabilities related to the Group, respectively. At all of our centers not serviced by the Group we have entered into long-term contracts with medical groups to provide professional services at those centers, including supervision and interpretation of diagnostic imaging procedures. The medical groups maintain full control over the physicians they employ. Through our management agreements, we make available to the medical groups the imaging centers, including all furniture, fixtures and medical equipment therein. The medical groups are compensated for their services from the professional component of the global net service fee revenue and after deducting management service fees paid to us, we have no economic controlling interest in these medical groups. As such, the financial results of these groups are not consolidated in our financial statements. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION – The operating activities of subsidiaries are included in the accompanying consolidated financial statements (“financial statements”) from the date of acquisition. Investments in companies in which we have the ability to exercise significant influence, but not control, are accounted for by the equity method. All intercompany transactions and balances, with our consolidated entities and the unsettled amount of intercompany transactions with our equity method investees, have been eliminated in consolidation. As stated in Note 1 above, the Group consists of VIEs and we consolidate the operating activities and balance sheets of each. USE OF ESTIMATES - The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates. REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to other centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and co-payment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans. Our total service fee revenues for the years ended December 31, 2023, 2022, and 2021 are presented in the table below. Our imaging center revenue is displayed as the estimated service fee, broken down by classification of insurance coverage type. Additional revenues are earned from our management services provided to joint ventures and our software and AI subsidiaries. In Thousands 2023 2022 2021 Commercial insurance $ 897,948 $ 785,128 $ 743,462 Medicare 363,863 311,124 280,911 Medicaid 43,175 38,279 34,731 Workers' compensation/personal injury 47,364 51,339 44,235 Other patient revenue 42,249 31,849 19,398 Management fee revenue 17,936 22,235 19,630 Software and teleradiology 18,082 14,238 10,525 Other 20,111 19,428 12,436 Revenue under capitation arrangements 153,433 152,045 148,334 Imaging center segment revenue 1,604,161 1,425,665 1,313,662 AI segment revenue 12,469 4,396 1,415 Total revenue $ 1,616,630 $ 1,430,061 $ 1,315,077 GOVERNMENT ASSISTANCE: COVID-19 PANDEMIC AND CARES ACT FUNDING - On March 11, 2020 the World Health Organization (WHO) designated COVID-19 as a global pandemic. To aid businesses and stimulate the national economy, Congress passed The Coronavirus Aid, Relief, and Economic Security ("CARES") Act, which was signed in to law on March 27, 2020. As part of the CARES act, we received $39.6 million total of accelerated Medicare payments which were recorded to deferred revenue in our consolidated balance sheet and are being applied to revenue as services are performed. Through December 31, 2023, all of the accelerated Medicare payments have been applied to revenue. ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. Amounts remaining to be collected on these agreements were $14.3 million and $15.4 million at December 31, 2023 and December 31, 2022, respectively. We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis. ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2023 2022 Accounts payable $ 122,888 $ 102,678 Accrued expenses 124,059 181,574 Accrued salary and benefits 71,297 62,072 Accrued professional fees 24,696 23,271 Total $ 342,940 $ 369,595 SOFTWARE REVENUE RECOGNITION – We have developed and sell Picture Archiving Communications Systems (“PACS”) and related services. The PACS sales are made primarily through our sales force and generally include hardware, software, installation, training and first-year warranty support. Hardware which is not unique or special purpose, is purchased from a third-party and resold to customers with a small mark-up. We have determined that our core software products, such as PACS, are essential to most of our arrangements as hardware, software and related services are sold as an integrated package. Revenue is recognized when a performance obligation is satisfied by transferring a promised good or service to a customer. For the years ended December 31, 2023, 2022 and 2021, we recorded approximately $20.2 million, $13.2 million, and $10.5 million, respectively, in revenue related to our software business which is included in net service fee revenue in our consolidated statements of operations. At December 31, 2023 we had deferred revenue of approximately $1.3 million associated with these sales which we expect to recognize into revenue over the next 12 months. SOFTWARE DEVELOPMENT COSTS – When we develop our own software and artificial intelligence solutions we capitalize and amortize those costs over their useful life. Costs related to the research and development of new software products and enhancements to existing software intended for resale to our customers are expensed as incurred. CONCENTRATION OF CREDIT RISKS – Financial instruments that potentially subject us to credit risk are primarily cash equivalents and accounts receivable. We have placed our cash and cash equivalents with one major financial institution. The cash in the financial institution is in excess of the amount insured by the Federal Deposit Insurance Corporation, or FDIC. Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections and maintain an allowance for bad debts based upon our historical collection experience. In addition, we have notes receivable stemming from our factoring of accounts receivable as stated above. Companies with which we factor our receivables are well known established buyers of such instruments, have agreed to assume the full risk of their collection. CASH AND CASH EQUIVALENTS – We consider all highly liquid investments that mature in three months or less when purchased to be cash equivalents. The carrying amount of cash and cash equivalents approximates the fair market value. DEFERRED FINANCING COSTS – Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs are related to our revolving credit facilities. Deferred financing costs, net of accumulated amortization, were $1.6 million and $2.3 million for the twelve months ended at December 31, 2023 and 2022, respectively. See Note 8, Credit Facilities and Notes Payable for more information on our revolving lines of credit. PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred. BUSINESS COMBINATIONS – When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations. GOODWILL AND INDEFINITE LIVED INTANGIBLES – Goodwill totaled $679.5 million and $677.7 million at December 31, 2023 and December 31, 2022, respectively. Indefinite lived intangible assets were $9.0 million at December 31, 2023 and $24.1 million at December 31, 2022 and are associated with the value of certain trade name intangibles and in process research and development ("IPR&D"). Goodwill, trade name intangibles and IPR&D are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. We tested goodwill, trade name and IPR&D for impairment on October 1, 2023. In September 2023, we determined that an IPR&D indefinite-lived intangible asset related to Aidence's Ai Veye Lung Nodule and Veye Clinic would not receive FDA approval for sale in the US without a new submission and additional expenditures for rework in the original projected timeline. The additional expenditures, delay and reduction of US sales affected the estimated fair value of the related IPR&D intangible asset and resulted in impairment charges of $3.9 million within Cost of operations in our Consolidated Statements of Operations . The estimated fair value of the IPR&D intangible asset was determined using the multi-period excess earnings method under the income approach, which estimates the present value of the free cash flows associated with the asset and tax amortization benefit to arrive at the fair value of the asset. Our annual impairment test as of October 1, 2023 noted no other impairment, and we have not identified any indicators of impairment through December 31, 2023. LONG-LIVED ASSETS – We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill and indefinite lived intangible assets, for impairment when events or changes indicate the carrying amount of an asset may not be recoverable. Accounting standards requires that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. At December 31, 2023 and December 31, 2021 we recorded lease abandonment of $2.5 million and $7.1 million, respectively in leasehold improvements for facilities that we abandoned. See the Leases discussion below for more information. Other than this, we determined that there were no events or changes in circumstances that indicated our long-lived assets were impaired during any periods presented. INCOME TAXES – Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. See Note 10, Income Taxes, for more information. LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of December 31, 2023. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order. We closely monitor patient levels at our imaging centers and occasionally divest or shut down centers to maximize utilization rates. We may abandon low utilization leases and divert the patients to nearby centers. During 2023, we experienced lower utilization at two imaging centers. To complete the closure of these locations, we took a lease abandonment charge of approximately $5.1 million and $19.7 million at December 31, 2023 and December 31, 2021, respectively. Of these amounts, $2.7 million and $12.6 million were related to right-of-use assets impairment and $2.5 million and $7.1 million were related to the write-off of leasehold improvements for the years ending December 31, 2023 and December 31, 2021. UNINSURED RISKS – We maintain a high-deductible workers’ compensation insurance policy. We have recorded liabilities of $3.4 million and $3.9 million at December 31, 2023 and December 31, 2022, respectively, for the estimated future cash obligations associated with the unpaid portion of the workers compensation claims incurred. We and our affiliated physicians carry an annual medical malpractice insurance policy that protects us for claims that are filed during the policy year and that fall within policy limits. The policy has a deductible which is $10,000 per incidence for all years covered by this report. In December 2008, in order to eliminate the exposure for claims not reported during the regular malpractice policy period, we purchased a medical malpractice claims made tail policy, which provides coverage for any claims reported in the event that our medical malpractice policy expires. As of December 31, 2023, this policy remains in effect. We have entered into an arrangement with Blue Shield to administer and process claims under a self-insured plan that provides health insurance coverage for our employees and dependents. We have recorded liabilities as of December 31, 2023 and 2022 of $7.2 million and $7.4 million, respectively, for the estimated future cash obligations associated with the unpaid portion of the medical and dental claims incurred by our participants. Additionally, we entered into an agreement with Blue Shield for a stop loss policy that provides coverage for any claims that exceed $250,000 up to a maximum of $1.0 million in order for us to limit our exposure for unusual or catastrophic claims. EMPLOYEE BENEFIT PLAN – We adopted a profit-sharing/savings plan pursuant to Section 401(k) of the Internal Revenue Code that covers substantially all non-professional employees. Eligible employees may contribute on a tax-deferred basis a percentage of compensation, up to the maximum allowable under tax law. Employee contributions vest immediately. We can elect to provide a matching contribution in the amount to a maximum of 1.0% per 4.0% of employee contributions. We contributed $0.0 million and $3.0 million in matching for each of the twelve months ended December 31, 2023 and December 31, 2022. EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated at various points in time: first on April 20, 2015, second on March 9, 2017, third on April 15, 2021 and currently as of April 27, 2023 (the “Restated Plan”). The Restated Plan was most recently approved by our stockholders at our annual stockholders meeting on June 7, 2023. We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We evaluate performance-based awards to determine if it is probable that the vesting conditions will be met. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three five FOREIGN CURRENCY TRANSLATION – For our operations in Canada, Europe and the United Kingdom, the functional currency of our foreign subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies are translated using the exchange rate at the balance sheet dates. Revenues and expenses are translated using average exchange rates prevailing during the reporting period. Any translation adjustments resulting from this process are shown separately as a component of accumulated other comprehensive income (loss). Gains and losses related to the foreign currency portion of international transactions are included in the determination of net income. The following is a reconciliation of Foreign Currency Translation amounts for the years ended December 31, 2023, 2022 and 2021 is provided below (in thousands): Currency Translation Balance as of December 31, 2020 (377) Currency Translation Adjustments (65) Balance as of December 31, 2021 (442) Currency Translation Adjustments (3,943) Balance as of December 31, 2022 (4,385) Currency Translation Adjustments 4,617 Balance as of December 31, 2023 232 OTHER COMPREHENSIVE INCOME (LOSS) – Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in other comprehensive income (loss). The components of other comprehensive income (loss) for the twelve month periods ended December 31, 2023, December 31, 2022, and December 31, 2021 are included in the consolidated statements of comprehensive income. COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected. DERIVATIVE INSTRUMENTS 2019 swaps : In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 swaps"). The 2019 swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They matured in October 2023 for the two smaller notional and will mature in October 2025 for the two larger notional. Under these arrangements, we arranged the 2019 swaps with locked in 1 month Term SOFR rates at 1.89% for the $100,000,000 notional and at 1.98% for the $400,000,000 notional. In October of 2023, the two agreements of $50,000,000 each matured and the remaining 2019 swaps have a total notional amount of $400,000,000 as of December 31, 2023. As of the effective date, we will be liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates remain above the arranged rates. At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of other accumulated comprehensive income (loss) in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. The cash flows for both our $400,000,000 notional interest rate swap contract locked in at 1.98% due October 2025 and our $100,000,000 notional interest rate swap contract locked in at 1.89% did not match the cash flows for our Barclays term loans and so we determined that they were not currently effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400,000,000 notional and after July 1, 2020 for the $100,000,000 notional was recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount will be amortized to interest expense through October 2023 at approximately $0.4 million per month and continuing at approximately $0.3 million per month through October 2025. A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective in 2020 is as follows (amounts in thousands): Interest Rate Contracts - Ineffective Portion For the twelve months ended Amount of gain (loss) recognized in income on derivative (current period ineffective portion) Location of gain (loss) recognized in Income on derivative (current period ineffective portion) Amount of loss reclassified from accumulated other comprehensive income (loss) into income (prior period effective portion) Location of loss reclassified from accumulated other comprehensive income (loss) into income (prior period effective portion) December 31, 2023 $(8,185) Other Income (Expense) $(3,576) Interest Expense December 31, 2022 $39,621 Other Income (Expense) $(3,687) Interest Expense December 31, 2021 $21,670 Other Income (Expense) $(3,695) Interest Expense Contingent Consideration : Aidence Holding B.V. On January 20, 2022, we completed our acquisition of all the equity interests of Aidence Holding B.V. ("Aidence") an artificial intelligence enterprise centered on lung cancer screening. As part of the purchase agreement, we agreed to pay up to $10.0 million consideration upon the completion of two identified milestones in RadNet common shares or cash at our election. The contingency had a fair value of approximately $7.2 million on December 31, 2022. The fair value is based on the yield rate of S&P B-rated corporate bonds and the probability of meeting the milestones which were tied to FDA approval of artificial intelligence screening solutions. In September 2023, we determined that the milestones could not be achieved under the contractual terms of the stock purchase agreement because the original submissions of artificial intelligence screening solutions did not receive regulatory clearance. A new submission would be required; and therefore, the probability of the milestones being achieved became zero. Accordingly, management recognized a gain of $7.2 million in 2023 representing the change in fair value of contingent consideration within Cost of operations in our Consolidated Statements of Operations . In addition, there was a general holdback of $4.0 million for any indemnification claims, which was settled on April 30, 2023 by the issuance of 144,227 shares of our common stock. Quantib B.V. On January 20, 2022, we completed our acquisition of all the equity interests of Quantib B.V. ("Quantib") an artificial intelligence enterprise centered on prostate cancer screening. As part of the purchase agreement, we agreed to issue 18 months after acquisition, 113,303 shares of our common stock with an initial fair value at the date of close of $3.0 million subject to adjustment for any indemnification claims and will be adjusted to fair value in subsequent periods. In addition, there is a general holdback of $1.6 million to be issued in cash subject to adjustment for any indemnification claims. On July 7, 2023, we settled the stock holdback contingent liabilities by issuing 113,303 shares of our common stock at an ascribed value of $3.5 million and also settled the general holdback for $1.6 million in cash. Montclair. On October 1, 2022, we completed our acquisition of Montclair Radiological Associates. As part of the purchase agreement, we recorded $1.2 million in contingent consideration which was based on the anticipated achievement of specific EBITDA targets within a defined time frame. In June 2023, we determined that the contingent consideration thresholds were not achieved and, as such, we recognized a gain of $1.2 million representing the change in fair value of the contingent consideration within Cost of operations in our Consolidated Statements of Operations . Heart & Lung Imaging Limited. On November 1, 2022, we completed our acquisition of 75% of the equity interests of Heart |
RECENT ACCOUNTING STANDARDS
RECENT ACCOUNTING STANDARDS | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
RECENT ACCOUNTING STANDARDS | RECENT ACCOUNTING STANDARDS Recently Issued Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures . The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its consolidated financial position and results of operations. In December 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-09 ("ASU 2023-09"), Income Tax (Topic 740) Improvements to Income Tax Disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and results of operations. |
BUSINESS COMBINATIONS AND RELAT
BUSINESS COMBINATIONS AND RELATED ACTIVITY | 12 Months Ended |
Dec. 31, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
BUSINESS COMBINATIONS AND RELATED ACTIVITY | BUSINESS COMBINATIONS AND RELATED ACTIVITY Acquisitions Imaging Center Segment During the years ended 2023, 2022 and 2021, we completed the acquisition of certain assets of the following entities, which either engage directly in the practice of radiology or associated businesses. The primary reason for these acquisitions was to strengthen our presence in the California, Delaware, Maryland, New Jersey and New York markets. We made a fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands): 2023: Entity Date Acquired Total Purchase Consideration Property & Equipment Right of Use Assets Goodwill Intangible Assets Other Right of Use Liabilities C.C.D.G.L.R. & S Services Inc.* 1/1/2023 3,500 435 1,689 3,015 50 — (1,689) Southern California Diagnostic Imaging, Inc.* 1/1/2023 1,815 466 1,184 1,272 50 27 (1,184) Inglewood Imaging Center, LLC* 2/1/2023 2,600 877 1,188 1,658 50 15 (1,188) Ramapo Radiology Associates, P.C.* 2/1/2023 2,000 1,663 3,775 229 100 8 (3,775) Madison Radiology Medical Group, Inc.* 4/1/2023 250 100 — 150 — — — Delaware Diagnostic Imaging, P.A.* 8/1/2023 600 401 337 149 50 — (337) Total $10,765 $3,942 $8,173 $6,473 $300 $50 $(8,173) *Fair Value Determination is Final 2022: Entity Date Acquired Total Purchase Consideration Property & Equipment Right of Use Assets Goodwill Intangible Assets Other Right of Use Liabilities IFRC LLC*^ 1/1/2022 8,200 2,910 1,703 5,271 — 19 (1,703) IFRC LLC*^ 1/1/2022 4,800 2,103 857 2,697 — — (857) Montclair Radiological Associates, P.A.*# 10/1/2022 94,877 16,414 4,665 79,690 400 (2,168) (4,124) Heart & Lung Imaging Limited+ 11/1/2022 32,000 — — 16,200 15,800 — — Chelsea Diagnostic Radiology, P.C.* 12/1/2022 2,800 568 — 2,132 100 — — North Jersey Imaging Center, LLC* 12/9/2022 104 20 — 55 25 4 — Total $142,781 $22,015 $7,225 $106,045 $16,325 $(2,145) $(6,684) *Fair Value Determination is Final ^ IFRC LLC acquisitions consisted of three subsidiaries of IFRC, one of which was purchased separately by a joint venture with Calvert Medical Imaging Centers, LLC. # Montclair Radiological Associates includes a liability for $1.2 million in contingent consideration. +See detailed description of the Heart & Lung Imaging Limited acquisition below. Heart & Lung Imaging Limited. On November 1, 2022, we acquired a 75% controlling interest in Heart & Lung Imaging Limited (“HLI”). HLI is a teleradiology concern which operates in the United Kingdom with the National Healthcare Service to screen high risk populations for cardiac and lung conditions. HLI’s operations are included in our imaging center segment for reporting purposes. The transaction was accounted for as the acquisition of a business with a total purchase consideration of approximately $31.9 million, including: i) shares with a fair value of $6.8 million (359,002 shares issued at $19.06 per share), ii) cash of $6.3 million, iii) contingent consideration of $10.8 million ($10.2 million in contingent milestone consideration and cash holdback of $0.6 million to be issued 24 months after acquisition subject to adjustment for any indemnification claims) and iv) noncontrolling interest of $8.0 million. We recorded $0.6 million in current assets, $15.8 million in intangible assets, $0.6 million current liabilities and $16.2 million in goodwill in connection with this transaction. As part of the purchase price allocation, we determined the identifiable intangible assets are customer relationships and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a rate of 19.0%. The cash flows were based on estimated earnings from existing customers, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. Artificial Intelligence Segment Aidence Holding B.V. On January 20, 2022, we completed our acquisition of all the equity interests of Aidence Holding B.V. ("Aidence") an artificial intelligence enterprise focused on lung cancer screening. Aidence is reported as part of our artificial intelligence segment and was acquired to enhance our AI capabilities. The transaction was accounted for as an acquisition of a business and total purchase consideration was determined to be approximately $45.2 million including i) 1,117,872 shares issued at $26.80 per share with a fair value of $30.0 million, ii) cash of $1.8 million, iii) contingent consideration of $11.9 million ($7.4 million in milestones to be settled in shares or cash at our election and a share holdback of $4.5 million), and iv) a settlement of a loan from RadNet of $1.5 million. In addition we paid certain seller closing costs through the issuance of 23,362 shares at a fair value of $0.6 million. As a result of this transaction, we recorded $1.0 million in current assets, $0.2 million in property and equipment, $27.7 million in intangible assets (including developed technology of $21.1 million and IPR&D of $5.5 million), $3.2 million in current liabilities, a deferred tax liability of $3.5 million, and $22.9 million in goodwill. In performing the purchase price allocation, we considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of the Aidence business. As part of the purchase price allocation, we determined the identifiable intangible assets are developed technology, IPR&D, trade names, and customer relationships. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 15% to 17%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology consists of artificial intelligence powered applications for lung nodule management and early lung cancer diagnosis and reporting. The IPR&D asset relates primarily to an in-process project for a customer relationship management offering to manage patients that are found with Incidental Pulmonary Nodules and has not reached technological feasibility as of the acquisition date. The asset recorded relates to one project, and the Company originally expected to complete the project following twelve months of acquisition. Subsequently, in September 2023, we determined that the In-process Research and Development ("IPR&D") related to Aidence's Ai Veye Lung and Veye Clinic would not achieve FDA approval for sale in the US without a new submission and additional expenditures for rework. The additional expenditures, delay, and reduction of US sales affected the estimated fair value of the associated IPR&D intangible asset and resulted in impairment charges of $3.9 million within Cost of operations in our Consolidated Statements of Operations . The useful lives for the developed technology asset was set at 7 years, for customer relationships 5.4 years, and trade names was 7 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the acquisition. These benefits include expanding the Company's AI capabilities to drive revenue growth. Quantib B.V. On January 20, 2022, we completed our acquisition of all the equity interests of Quantib B.V. ("Quantib") an artificial intelligence enterprise focused on prostate cancer screening. Quantib is reported as part of our artificial intelligence segment, and was acquired to enhance our AI capabilities. The transaction was accounted for as an acquisition of a business and total purchase consideration was determined to be approximately $42.3 million including i) 965,058 shares issued at $26.80 per share with a fair value of $25.9 million, ii) cash of $11.8 million, and iii) contingent consideration consisting of 113,303 shares with a fair value at the date of close of $3.0 million and cash of $1.6 million both to be released 18 months after acquisition subject to adjustment for any indemnification claims. As a result of this transaction, we recorded $2.4 million in current assets, $0.1 million in property and equipment, $21.3 million in intangible assets (including developed technology of $19.6 million and IPR&D of $0.7 million), $0.7 million in current liabilities, $6.7 million in long-term debt and deferred tax liabilities, and $26.4 million in goodwill. In performing the purchase price allocation, we considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of the Quantib business. As part of the purchase price allocation, we determined the identifiable intangible assets are developed technology, IPR&D, trade names, and customer relationships. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 50% to 55%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology consists of artificial intelligence powered applications for neurological and prostate imaging scans and reporting. The useful lives for the developed technology asset was set at seven years, customer relationships three years, and trade names seven years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the acquisition. These benefits include expanding the Company's AI capabilities to drive revenue growth. As disclosed above, for the acquisitions of Aidence and Quantib, the Company uses the income approach to determine the fair value of developed technology and IPR&D acquired in business combinations. This approach determines fair value by estimating the after-tax cash flows attributable to the respective assets over their useful lives and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. The value of the in-process projects is based on the project's stage of completion, the complexity of the work completed as of the acquisition date, the projected costs to complete, the expected introduction date, the estimated cash flows to be generated upon commercial release and the estimated useful life of the technology. The Company believes that the estimated developed technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party would pay for the assets. The significant assumptions used to estimate the fair value of intangible assets include discount rates and certain assumptions that form the basis of the forecasted results, specifically, revenue growth rates, EBITDA margins and obsolescence factors. These significant assumptions are forward looking and could be affected by future economic and market conditions. Subsidiary activity Formation of majority owned subsidiaries Frederick County Radiology, LLC. On April 1, 2022 we formed Frederick County Radiology, LLC ("FCR"), a partnership with Frederick Health Hospital, Inc. The operation offers multi-modality services out of six locations in Frederick, Maryland. We contributed the operations of four centers to the enterprise and Frederick Health Hospital, Inc. contributed $5.4 million in fixed assets, $3.0 million in equipment, and $11.0 million in goodwill. As a result of the transaction, we recognized a gain of $6.6 million to additional paid in capital and retained a 65% controlling economic interest in FCR and Frederick Health Hospital, Inc. retains an $11.1 million or 35% noncontrolling economic interest in FCR. Formation of majority owned subsidiary and sale of ownership interest Los Angeles Imaging Group, LLC. On September 1, 2023 we formed a wholly-owned subsidiary, Los Angeles Imaging Group, LLC ("LAIG"). The operation offers multi-modality imaging services out of three locations in Los Angeles, California. We contributed the operations of 3 centers to the subsidiary. Cedars-Sinai Medical Center purchased from us a 35% noncontrolling economic interest in LAIG for a cash payment of $5.9 million. As a result of the transaction, we retain a 65% controlling economic interest in LAIG. Sale of ownership interest in a majority owned subsidiary Tarzana Medical Center, LLC. Effective September 1, 2021 we completed the sale of a 24.9% ownership interest in our majority owned subsidiary West Valley Imaging Group, LLC for $13.1 million to Tarzana Medical Center, LLC. After the sale, our ownership interest in the subsidiary has reduced from 75.0% to 50.1% and we retain a controlling financial interest in the subsidiary. We recognized in additional paid in capital on our consolidated balance sheets, $4.2 million excess in consideration over the carrying value of the sold economic interest. Post the sale of our ownership interest we acquired from Tarzana Medical Center, LLC, certain tangible and intangible business assets for purchase consideration of approximately $5.2 million. |
SEGMENT REPORTING
SEGMENT REPORTING | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
SEGMENT REPORTING | SEGMENT REPORTING Our reportable segments are described below: Imaging Center Our Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a strategy that diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. We also provide teleradiology services in the United Kingdom though our majority-owned Heart & Lung Imaging Limited subsidiary. Included in the segment is our eRad subsidiary, which designs the underlying critical scheduling, data storage and retrieval systems necessary for imaging center operation. Artificial Intelligence ("AI") Our AI segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. Our chief operating decision maker ("CODM"), who is also our CEO, evaluates the financial performance of our segments based upon their respective revenue and segmented internal profit and loss statements prepared on a basis not consistent with GAAP. We do not report balance sheet information by segment since it is not reviewed by our CODM. In the normal course of business, our reportable segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results. Twelve Months Ended December 31, 2023 Imaging Centers AI Intersegment Elimination Consolidated Total Revenue: Third Party $ 1,610,707 $ 5,923 $ — $ 1,616,630 Intersegment — 6,546 (6,546) — Total revenue $ 1,610,707 $ 12,469 $ (6,546) $ 1,616,630 Twelve Months Ended December 31, 2022 Imaging Centers AI Intersegment Elimination Consolidated Total Revenue: Third Party $ 1,425,665 $ 4,396 $ — $ 1,430,061 Intersegment — — — — Total revenue $ 1,425,665 $ 4,396 $ — $ 1,430,061 The table below present segment information reconciled to our financial results, with segment operating income or loss including revenue less cost of operations, depreciation and amortization, and other operating expenses to the extent specifically identified by segment (in thousands): Twelve Months Ended December 31, 2023 2022 2021 Revenue: Imaging Centers $ 1,604,161 $ 1,425,665 $ 1,313,662 AI 12,469 4,396 1,415 Total revenue $ 1,616,630 $ 1,430,061 $ 1,315,077 Cost of Operations Imaging Centers $ 1,371,036 $ 1,240,593 $ 1,117,941 AI 24,203 23,753 5,333 Total cost of operations $ 1,395,239 $ 1,264,346 $ 1,123,274 Gain on contribution of imaging centers into joint venture Imaging Centers $ (16,808) $ — $ — AI — — — Total cost of operations $ (16,808) $ — $ — Lease abandonment charges Imaging Centers $ 5,146 $ — $ 19,675 AI — — — Total depreciation and amortization $ 5,146 $ — $ 19,675 Depreciation and Amortization Imaging Centers $ 120,776 $ 109,524 $ 96,174 AI 7,615 6,353 520 Total depreciation and amortization $ 128,391 $ 115,877 $ 96,694 Loss on Disposal of Equipment Imaging Centers $ 2,191 $ 2,506 $ 1,246 AI (4) 23 — Total loss (gain) $ 2,187 $ 2,529 $ 1,246 Severance Imaging Centers $ 1,973 $ 926 $ 744 AI 1,805 20 — Total severance $ 3,778 $ 946 $ 744 Income from Operations Imaging Centers $ 119,847 $ 72,116 $ 77,882 AI (21,150) (25,753) (4,438) Total income from operations $ 98,697 $ 46,363 $ 73,444 In the first quarter of 2024, we revised our reportable segments to combine our eRad business, which was included in the Imaging Center segment, with our AI segment to form a new Digital Health reportable segment. As a result of the change, beginning with our Quarterly Report on Form 10-Q for the quarter ending March 31, 2024, we will report our results in these two reportable segments. The change in reportable segments will be reflected retrospectively. |
GOODWILL AND OTHER INTANGIBLE A
GOODWILL AND OTHER INTANGIBLE ASSETS | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill is recorded as a result of business combinations. The following is a reconciliation of Goodwill by business segment for the years ended December 31, 2022 and December 31, 2023 is provided below (in thousands): Imaging Center Artificial Intelligence Total Balance as of December 31, 2021 $ 489,210 $ 24,610 $ 513,820 Additions 120,551 48,697 169,248 Disposals (4,200) — (4,200) Measurement period and other adjustments (106) 147 41 Currency translation 1,028 (2,272) (1,244) Balance as of December 31, 2022 $ 606,483 $ 71,182 $ 677,665 Additions 6,473 — 6,473 Disposals (9,235) — (9,235) Measurement period and other adjustments 1,603 — 1,603 Currency translation 1,233 1,724 2,957 Balance as of December 31, 2023 $ 606,557 $ 72,906 $ 679,463 The amount of goodwill from these acquisitions that is deductible for tax purposes as of December 31, 2023 is $142.7 million. Other intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names. Total amortization expense was $12.2 million, $10.1 million, and $4.4 million for the years ended December 31, 2023, 2022 and 2021, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management service agreements are amortized over 25 years using the straight line method. Software development is capitalized and amortized over the useful life of the software when placed into service. Trade names are reviewed annually for impairment. The following tables shows annual amortization expense, by asset classes that will be recorded over the next five years (in thousands): 2024 2025 2026 2027 2028 Thereafter Total Weighted average amortization period remaining in years Management Service Contracts $ 2,287 $ 2,287 $ 2,287 $ 2,287 $ 2,287 $ 6,671 $ 18,106 7.9 Covenant not to compete and other contracts 946 714 427 132 45 6 2,270 3.4 Customer Relationships 1,234 1,104 981 797 764 10,564 15,444 17.7 Patent and Trademarks 316 316 316 315 300 164 1,727 5.8 Developed Technology & Software 7,785 7,785 7,745 7,210 7,046 6,117 43,688 5.7 Trade Names amortized 77 77 77 77 63 27 398 5.3 Trade Names indefinite life — — — — — 7,100 7,100 — IPR&D — — — — — 1,882 1,882 — Total Annual Amortization $ 12,645 $ 12,283 $ 11,833 $ 10,818 $ 10,505 $ 32,531 $ 90,615 |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY AND EQUIPMENT | PROPERTY AND EQUIPMENT Property and equipment and accumulated depreciation and amortization are as follows (in thousands): December 31, 2023 2022 Land $ 250 $ 250 Medical equipment 714,400 649,034 Computer and office equipment, furniture and fixtures 127,540 119,467 Software costs 47,286 36,015 Leasehold improvements 537,853 501,963 Equipment originally acquired under finance/capital lease 13,971 13,971 Total property and equipment cost 1,441,300 1,320,700 Accumulated depreciation (836,899) (754,739) Total property and equipment $ 604,401 $ 565,961 Included in our property and equipment at December 31, 2023 is approximately $42.7 million total of construction in process amounts consisting of $12.2 million in medical equipment, $1.9 million in computer and office equipment, $6.0 million in software costs and $22.6 million in leasehold improvements. Included in our property and equipment at December 31, 2022 is approximately $73.4 million total of construction in process amounts consisting of $26.6 million in medical equipment, $5.3 million in computer and office equipment, $0.4 million in software costs and $41.1 million in leasehold improvements. |
CREDIT FACILITIES AND NOTES PAY
CREDIT FACILITIES AND NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
CREDIT FACILITIES AND NOTES PAYABLE | 3.50x 3.25% 2.25% > 3.00x but ≤ 3.50x 3.00% 2.00% ≤ 3.00x 2.75% 1.75% As of December 31, 2023, the effective interest rate for borrowings on revolving loans under the Barclays Revolving Credit Facility was 10.3%. For letters of credit issued under the Barclays Revolving Credit Facility, letter of credit fees accrue at the applicable margin for SOFR revolving loans which is currently 3.00% and fronting fees accrue at 0.125% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the Barclays Restated Credit Agreement. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Barclays Revolving Credit Facility. The Barclays Revolving Credit Facility will terminate on April 23, 2026 unless otherwise accelerated in accordance with the terms of the Barclays Restated Credit Agreement. Truist Revolving Credit Facility: Associated with the Truist Revolving Credit Facility of $50.0 million are deferred financing costs, net of accumulated amortization, of $0.5 million at December 31, 2023. As of December 31, 2023, NJIN had no borrowings under the Truist Revolving Credit Facility. The Truist Revolving Credit Facility bears interest with different margins based on types of borrowings at a Pricing Level V as noted in the pricing grid above. The Truist Revolving Credit Facility terminates on the earliest of (i) October 7, 2027, (ii) the date on which the Revolving Commitments are terminated pursuant to Section 2.8 of the Truist Restated Credit Agreement, or (iii) the date on which all amounts outstanding under the Truist Restated Credit Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise). Recent Amendments to prior Credit Facilities Truist Credit Facilities: On August 31, 2018, under an Amended and Restated Revolving Credit and Term Loan Agreement, our NJIN subsidiary secured a term loan commitment of $60.0 million and established revolving credit facility of $30.0 million. The agreement had a maturity date of August 31, 2023 and was refinanced on October 10, 2022 by the Truist Restated Credit Agreement." id="sjs-B4">CREDIT FACILITIES AND NOTES PAYABLE As of December 31, 2023 and December 31, 2022 our term loan debt and other obligations consisted of the following (in thousands): December 31, 2023 December 31, 2022 Barclays Term Loans collateralized by RadNet's tangible and intangible assets $ 678,687 $ 714,125 Discount on Barclays Term Loans (9,041) (11,127) Truist Term Loan collateralized by NJIN's tangible and intangible assets 144,375 150,000 Discount on Truist Term Loan (990) (1,254) Equipment notes payable at 6.0%, due 2028, collateralized by medical equipment 17,011 — Total debt obligations 830,042 851,744 Less current portion (17,974) (12,400) Long-term portion of debt obligations $ 812,068 $ 839,344 The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities for years ending December 31 (in thousands) 2024 $ 20,324 2025 22,431 2026 22,676 2027 124,188 2028 650,454 Total notes payable obligations $ 840,073 We had no outstanding balance under our $195.0 million Barclays Revolving Credit Facility at December 31, 2023 and had reserved an additional $7.6 million for certain letters of credit. The remaining $187.4 million of our Barclays Revolving Credit Facility was available to draw upon as of December 31, 2023. We also had no balance under our $50.0 million Truist Revolving Credit Facility, related to our consolidated subsidiary NJIN, at December 31, 2023, and with no letters of credit reserved against the facility, the full amount was available to draw upon. At December 31, 2023 we were in compliance with all covenants under our credit facilities. On February 1, 2023, we issued a promissory note in the amount of $19.8 million to acquire radiology equipment previously leased under operating leases. Amendments to Credit Facilities Barclays: First Amendment to Second Amended and Restated First Lien Credit and Guaranty Agreement On March 27, 2023, we entered into the First Amendment to Second Amended and Restated First Lien Credit and Guaranty Agreement related to our Barclays credit facility (the "Barclays Amendment"), which replaces the interest rate benchmark, from the London Interbank Offered Rate ("LIBOR") to the Secured Overnight Financing Rate ("SOFR") and includes applicable credit spread adjustments of 0.11448%, 0.26161%, and 0.42826% for interest periods of one month, three months, and six months, respectively. The replacement of LIBOR with SOFR and the credit spread adjustments were effective as of March 31, 2023, which was the last day of the last-ending existing interest period of currently outstanding loan bearing interest at LIBOR. Other than the foregoing, the material terms of the Barclays credit facility remained unchanged. Barclays: Second Amended and Restated First Lien Credit and Guaranty Agreement On April 23, 2021, we entered into the Second Amended and Restated First Lien Credit and Guaranty Agreement (the "Barclays Restated Credit Agreement") which provides for $725.0 million of senior secured first lien term loans (the "Barclays Term Loans") and a $195.0 million senior secured revolving credit facility (the "Barclays Revolving Credit Facility"). The proceeds of the Barclays Term Loans were used to refinance loans outstanding under our prior Barclays credit agreement and provide funding for current and future operations. Total costs of the Barclays Restated Credit Agreement amounted to approximately $14.9 million segregated as follows: $8.8 million capitalized to discount and deferred finance cost, $4.5 million expensed to debt restructuring costs, $1.5 million charged to loss on early extinguishment of debt and $0.1 million written off to interest expense. Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Restated Credit Agreement. Truist: Second Amended and Restated Revolving Credit and Term Loan Agreement On October 7, 2022, we entered into the Second Amended and Restated Revolving Credit and Term Loan Agreement (the "Truist Restated Credit Agreement") which provides for a $150.0 million of a secured term loan (the "Truist Term Loan") and a $50.0 million secured revolving credit facility (the "Truist Revolving Credit Facility"). Both loans were secured by our simultaneous entry into the Second Amended and Restated Guaranty and Security Agreement on the same date. The proceeds were were used to refinance the outstanding balance under our prior Truist term loan agreement and provide funding for current and future operations. Total costs of the Truist Restated Credit Agreement amounted to approximately $2.7 million segregated as follows: $2.0 million capitalized to discount and deferred finance cost and $0.7 million expensed to loss on extinguishment of debt and related expenses in other expense. Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Truist Restated Credit Agreement. All obligations under the Truist Restated Credit Agreement bear interest at either a SOFR or a Base Rate (each as defined in the Truist Restated Credit Agreement), plus an applicable margin according to the following schedule: Pricing Level Leverage Ratio Applicable Margin for SOFR Loans Applicable Margin for Base Rate Loans Applicable Margin for Letter of Credit Fees Applicable Percentage for Commitment Fee I Greater than or equal to 3.00:1.00 2.50% per annum 1.50% per annum 2.50% per annum 0.45% per annum II Less than 3.00:1.00 but greater than or equal to 2.50:1.00 2.25% per annum 1.25% per annum 2.25% per annum 0.40% per annum III Less than 2.50:1.00 but greater than or equal to 2.00:1.00 2.00% per annum 1.00% per annum 2.00% per annum 0.35% per annum IV Less than 2.00:1.00 but greater than or equal to 1.50:1.00 1.75% per annum 0.75% per annum 1.75% per annum 0.30% per annum V Less than 1.50:1.00 1.50% per annum 0.50% per annum 1.50% per annum 0.30% per annum Senior Credit Facilities: Barclays Term Loans: Through March 31, 2023, the Barclays Term Loans bore interest at either a Eurodollar Rate or an Alternative Base Rate (in each such case, as defined in the Barclays Restated Credit Agreement) plus an applicable margin. The applicable margin for Eurodollar Rate and Alternative Base Rate was 3% and 2%, respectively, with an effective Eurodollar Rate and the Alternative Base Rate of 4.63% and 8.00%, respectively. Under the Barclays Amendment, effective March 31, 2023, the Barclays Term Loans bear interest either at a SOFR or Alternative Base Rate (in each such case, as defined in the Restated Barclays Credit Agreement) plus an applicable margin. The applicable margin for Eurodollar Rate and Alternative Base Rate was 3% and 2%, respectively. At December 31, 2023, we have an effective SOFR of 8.38%, with an applicable credit spread adjustment of 0.26161%, and an Alternative Base Rate of 10.5%, respectively. The Barclays Restated Credit Agreement provides for quarterly payments of principal for the Barclays Term Loans in the amount of approximately $1.8 million. The Barclays Term Loans will mature on April 23, 2028 unless otherwise accelerated under the terms of the Barclays Restated Credit Agreement. Truist Term Loan: The Truist Term Loan currently bears interest at a three month SOFR election of 5.33% plus an applicable margin and fees based on Pricing Level V described above. The scheduled amortization of the Truist Term Loan began March 31, 2023 with quarterly payments of $1.9 million, representing 1.00% of the original principal balance. At scheduled intervals, the quarterly amortization increases by $0.9 million, with the remaining balance to be paid at maturity. The Truist Term Loan will mature on October 10, 2027 unless otherwise accelerated under the terms of the Truist Restated Credit Agreement. Revolving Credit Facilities: Barclays Revolving Credit Facility: The Barclays Revolving Credit Facility is a $195.0 million senior secured revolving credit facility. Associated with the Barclays Revolving Credit Facility are deferred financing costs, net of accumulated amortization, of $1.1 million at December 31, 2023. Revolving loans borrowed under the Barclays Revolving Credit Facility bear interest at either a SOFR or an Alternate Base Rate (in each case, as defined in the Barclays Restated Credit Agreement) plus an applicable margin which adjusts depending on our net leverage ratio, according to the following schedule: Net Leverage Ratio Term SOFR Loans Alternative Base Rate Spread > 3.50x 3.25% 2.25% > 3.00x but ≤ 3.50x 3.00% 2.00% ≤ 3.00x 2.75% 1.75% As of December 31, 2023, the effective interest rate for borrowings on revolving loans under the Barclays Revolving Credit Facility was 10.3%. For letters of credit issued under the Barclays Revolving Credit Facility, letter of credit fees accrue at the applicable margin for SOFR revolving loans which is currently 3.00% and fronting fees accrue at 0.125% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the Barclays Restated Credit Agreement. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Barclays Revolving Credit Facility. The Barclays Revolving Credit Facility will terminate on April 23, 2026 unless otherwise accelerated in accordance with the terms of the Barclays Restated Credit Agreement. Truist Revolving Credit Facility: Associated with the Truist Revolving Credit Facility of $50.0 million are deferred financing costs, net of accumulated amortization, of $0.5 million at December 31, 2023. As of December 31, 2023, NJIN had no borrowings under the Truist Revolving Credit Facility. The Truist Revolving Credit Facility bears interest with different margins based on types of borrowings at a Pricing Level V as noted in the pricing grid above. The Truist Revolving Credit Facility terminates on the earliest of (i) October 7, 2027, (ii) the date on which the Revolving Commitments are terminated pursuant to Section 2.8 of the Truist Restated Credit Agreement, or (iii) the date on which all amounts outstanding under the Truist Restated Credit Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise). Recent Amendments to prior Credit Facilities Truist Credit Facilities: On August 31, 2018, under an Amended and Restated Revolving Credit and Term Loan Agreement, our NJIN subsidiary secured a term loan commitment of $60.0 million and established revolving credit facility of $30.0 million. The agreement had a maturity date of August 31, 2023 and was refinanced on October 10, 2022 by the Truist Restated Credit Agreement. |
LEASES
LEASES | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
LEASES | LEASES Our material lease contracts are for facilities and advanced radiology equipment. In regards to our imaging, administrative and warehouse facilities, the most common initial lease term varies in length from 5 to 15 years. Including renewal options negotiated with the landlord, we can have a total span of 10 to 35 years at these locations, and we do not enter into purchase options on the underlying property. We also lease smaller satellite X-Ray locations on mutually renewable terms, usually lasting one year. Leases for advanced radiology and office equipment have terms generally lasting from 5 to 8 years. All leases are classified as operating or finance for accounting purposes, depending on the terms of the agreement. Our incremental borrowing rate used to discount the stream of lease payments is closely related to the interest rates charged on our collateralized debt obligations and our incremental borrowing rate is adjusted when those rates experience a substantial change. During 2021, we satisfied all liabilities classified as finance leases, and only operating leases remain. The components of lease expense were as follows: Years ended December 31, (In thousands) 2023 2022 2021 Operating lease cost (1) $ 106,954 $ 107,475 $ 121,578 Finance lease cost: Depreciation of leased equipment $ 1,204 $ 2,896 $ 3,068 Interest on lease liabilities — — 46 Total finance lease cost $ 1,204 $ 2,896 $ 3,114 1) Operating lease cost above for the year ended December 31, 2023 and 2021 included $2.7 million and $12.6 million, respectively in lease abandonment charges. Please see our discussion in the Leases section of Note 2, Summary of Significant Accounting Policies. Supplemental cash flow information related to leases was as follows: Years ended December 31, (In thousands) 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 101,516 $ 108,004 $ 110,288 Operating cash flows from financing leases — — 46 Financing cash flows from financing leases — — 3,304 Right-of-use & Equipment assets obtained in exchange for lease obligations: Operating leases 55,852 88,080 186,695 Supplemental balance sheet information related to leases was as follows: (In thousands, except lease term and discount rates) December 31, 2023 2022 Operating Leases Operating lease right-of-use assets $ 596,032 $ 603,524 Current portion of operating lease liability 55,981 57,607 Long-term operating lease liability 605,097 604,117 Total operating lease liabilities $ 661,078 $ 661,724 Finance Leases Equipment at cost $ 13,971 $ 13,971 Accumulated depreciation (13,374) (12,171) Equipment, net $ 597 $ 1,801 Weighted Average Remaining Lease Term Operating leases - years 10.6 10.9 Weighted Average Discount Rate Operating leases 6.7 % 6.4 % Maturities of lease liabilities were as follows: (In thousands) Operating Leases Year Ending December 31, 2024 $ 97,603 2025 $ 92,092 2026 91,400 2027 88,977 2028 85,633 Thereafter 482,594 Total Lease Payments 938,299 Less imputed interest (277,221) Total $ 661,078 As of December 31, 2023, we have additional operating leases for facilities and medical equipment that have not yet commenced of approximately $4.6 million. These operating leases will commence in 2024 with lease terms of 1 to 15 years. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES For the years ended December 31, 2023, 2022 and 2021, we have the following income (loss) before income taxes (in thousands): December 31, 2023 2022 2021 US Domestic $ 60,374 $ 59,529 $ 58,806 Foreign (21,564) (16,560) 73 Income (loss) before income taxes $ 38,810 $ 42,969 $ 58,879 For the years ended December 31, 2023, 2022 and 2021, we recognized income tax expense comprised of the following (in thousands): December 31, 2023 2022 2021 Federal current tax $ — $ — $ — State current tax 3,442 371 (2,191) Foreign current tax 638 87 18 Other current tax — — — Federal deferred tax 8,960 6,470 9,831 State deferred tax (2,724) 5,863 6,902 Foreign deferred tax (1,843) (3,430) — Currency translation — — — Income tax expense 8,473 9,361 14,560 A reconciliation of the statutory U.S. federal rate and effective rates is as follows: Years Ended December 31, 2023 2022 2021 Federal tax $ 8,150 $ 9,023 $ 12,365 State franchise tax, net of federal benefit 3,730 595 4,198 Other Non deductible expenses 196 305 (93) Officer Compensation 1,199 759 291 Noncontrolling interests in partnerships (5,752) (4,821) (4,114) Changes in valuation allowance (2,569) 6,124 (249) Return to provision 5,987 234 (2,530) Deferred true-ups and other 483 (1,451) 5,009 Foreign rate differential (1,083) (737) 4 Uncertain tax provisions (884) (749) (321) Tax rate adjustment (984) — — Other differences — 79 — Income tax expense $ 8,473 $ 9,361 $ 14,560 Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial and income tax reporting purposes and operating loss carryforwards. Our deferred tax assets and liabilities comprise the following (in thousands): December 31, Deferred tax assets: 2023 2022 Net operating losses $ 43,247 $ 68,124 Accrued expenses 4,432 3,941 Operating lease liability 136,097 142,347 Equity compensation 4,179 4,387 Allowance for doubtful accounts 2,198 3,071 Other 15,755 6,541 Valuation allowance (9,688) (12,095) Total Deferred Tax Assets $ 196,220 $ 216,316 Deferred tax liabilities: Property and equipment (7,851) (9,214) Goodwill (42,419) (38,820) Intangibles (15,578) (18,640) Operating lease right-of-use asset (122,840) (129,802) Outside basis difference (18,547) (20,015) Other (4,761) (9,081) Total Deferred Tax Liabilities $ (211,996) $ (225,572) Net Deferred Tax Liability $ (15,776) $ (9,256) As of December 31, 2023, we had federal net operating loss carryforwards of approximately $128.9 million, which is comprised of definite and indefinite net operating losses. We had federal net operating loss carryforwards of approximately $63.9 million, which expire at various intervals from the years 2026 to 2037, and had carryforwards of $65.0 million of net operating losses which do not expire. Federal net operating losses generated in tax years following December 31, 2017 carryover indefinitely and may be used to offset up to 80% of future taxable net income. We also had state net operating loss carryforwards of approximately $145.3 million, which expire at various intervals from the years 2024 through 2042. As of December 31, 2023, $24.9 million of our federal net operating loss carryforwards acquired in connection with the 2011 acquisition of Raven Holdings U.S., Inc. and the 2019 acquisition of Nulogix Health, Inc. are subject to limitations related to their utilization under Section 382 of the Internal Revenue Code. We also had foreign net operating loss carryforwards of approximately $45.8 million, which do not expire and are carried over indefinitely. We considered all evidence available when determining whether deferred tax assets are more likely-than-not to be realized, including projected future taxable income, scheduled reversals of deferred tax liabilities, prudent tax planning strategies, and recent financial operations. The evaluation of this evidence requires significant judgment about the forecasts of future taxable income, based on the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income. As of December 31, 2023, we have determined that deferred tax assets of $196.2 million are more likely-than-not to be realized. We have also determined deferred tax liabilities of $42.4 million are related to book basis in goodwill that has an indefinite life. We file consolidated income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. We continue to reinvest earnings of the non-US entities for the foreseeable future and therefore have not recognized any U.S. tax expense on these earnings. With limited exceptions, we are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2018. We do not anticipate the results of any open examinations would result in a material change to our financial position. A reconciliation of the total gross amounts of unrecognized tax benefits for the years ended are as follows (in thousands): December 31, 2023 2022 2021 Balance at beginning of year $ 4,144 $ 5,088 $ 5,484 Increases related to prior year tax positions 54 55 317 Increases related to current year tax positions 62 — — Expiration of the statute of limitations for the assessment of taxes (1,180) (999) (713) Increase related to change in rate 2 — — Balance at end of year $ 3,082 $ 4,144 $ 5,088 At December 31, 2023, we had unrecognized tax benefits of $3.1 million of which $2.5 million will affect the effective tax rate if recognized. We recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the year ended December 31, 2023 the Company accrued approximately $47 thousand of interest and penalties. As of December 31, 2023, accrued interest and penalties amounted to approximately $0.4 million. We do not anticipate the uncertain tax position to change materially within the next 12 months. In 2021, the Organization for Economic Co-operation and Development ("OECD") announced an inclusive framework on base erosion and profit shifting including Pillar Two Model Rules defining the global minimum tax, which calls for taxation of large multinational corporations at a minimum rate of 15%. Subsequently multiple sets of administrative guidance have been issued. Many non-US tax jurisdictions have either recently enacted legislation to adopt certain components of Pillar Two Model Rules beginning in 2024 (including the European Union Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. We are continuing to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the jurisdictions that we operate in outside of the US. The Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act of 2022 was signed into law on August 9, 2022 to boost domestic semiconductor manufacturing and encourage US research activities. The act provided a 25% investment credit intended to promote domestic production of semiconductors. This act is not expected to have a material impact for us. |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION Stock Incentive Plans We have one long-term equity incentive plan, the RadNet, Inc. Equity Incentive Plan, which we first amended and restated April 20, 2015, second on March 9, 2017, third on April 15, 2021, and currently as of April 27, 2023 (the "Restated Plan”). The Restated Plan was most recently approved by our stockholders at our annual stockholders meeting on June 7, 2023. We have reserved for issuance under the Restated Plan 20,100,000 shares of common stock. We can issue options (incentive and nonstatutory), performance based options, stock awards (restricted or unrestricted), stock units, performance based stock units, and stock appreciation rights under the Restated Plan. Options Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over one five The following summarizes all of our option transactions for the twelve months ended December 31, 2023: Outstanding Options Shares Weighted Average Weighted Average Aggregate Balance, December 31, 2022 678,914 $ 15.72 Granted 261,220 18.64 Exercised (12,723) 11.11 Canceled, forfeited or expired (16,000) 17.06 Balance, December 31, 2023 911,411 16.60 6.22 $ 16,561,659 Exercisable at December 31, 2023 668,809 14.75 5.24 13,387,921 Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on December 31, 2023 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on December 31, 2023. As of December 31, 2023, total unrecognized stock-based compensation expense related to non-vested employee awards was $1.4 million which is expected to be recognized over a weighted average period of approximately 1.23 years. DeepHealth Options During the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted 412,434 options at a grant date fair value of $16.93 per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of December 31, 2023, total unrecognized stock based compensation expense related to non-vested DeepHealth options was insignificant. Outstanding Options Shares Weighted Average Weighted Average Aggregate Balance, December 31, 2022 116,982 Exercised (37,909) — Balance, December 31, 2023 79,073 — 5.75 $ 2,749,368 Exercisable at December 31, 2023 76,612 — 5.75 2,663,803 Options issued in replacement of original DeepHealth options as a result of our acquisition are not included in the share count under the Restated Plan. Restricted Stock Awards (“RSA’s”) The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of December 31, 2023, we have issued a total of 8,718,185 RSA’s of which 537,358 were unvested at December 31, 2023. The following summarizes all unvested RSA’s activities during the twelve months ended December 31, 2023: RSA's Weighted-Average Weighted-Average RSA's unvested at December 31, 2022 536,767 $ 23.84 Changes during the period Granted 825,255 $ 21.31 Vested (785,656) $ 22.12 Forfeited (39,008) $ 18.31 RSA's unvested at December 31, 2023 537,358 0.90 $ 22.99 We determine the fair value of all RSA’s based on the closing price of our common stock on award date. Other stock bonus awards The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the twelve months ended December 31, 2023 we issued 50,765 shares relating to these awards, amounting to approximately $1.3 million of compensation expense. Performance based stock units ("PSUs") In January 2022, we granted certain employees PSUs with a target award of 25,683 shares of our common stock. The PSUs will vest in two equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 200% of the target award) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2022 through December 31, 2022. In January of 2023, based on the performance condition achieved, the board of directors issued 12,843 units with a fair value of $29.44 per unit. In January 2023, we granted certain employees PSUs with a target award of 60,685 shares of our common stock. The PSUs will vest in two equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 200% of the target award) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2023 through December 31, 2023. As of December 31, 2023, 121,370 shares are expected to vest. Performance based stock options ("PSOs") In January 2022, we granted certain employees PSOs to purchase a maximum of 111,925 shares of our common stock. The PSOs will vest in three equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0 shares to 111,925 shares) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2022 through December 31, 2022. In January of 2023, based on the performance condition achieved, the board of directors issued 27,981 options with a strike price of $29.44 per share. In January 2023, we granted certain employees PSOs with a potential to purchase a maximum of 235,227 shares of our common stock. The PSOs will vest in three equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0 shares to 235,227 shares) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period January 1, 2023 through December 31, 2023. As of December 31, 2023, all 235,227 shares are expected to vest. AI Long Term Incentive Plan shares ("AI LTIPs") In addition, we issue stock-based compensation to certain employees in our AI segment in the form of Stock Units and Restricted Stock Awards, subject to certain restrictions. The awards represent a form of long term incentive and are reflective of a general practice within the software industry. The units and shares vest ratably over a two The following summarizes all unvested AI LTIPs activities during the twelve months ended December 31, 2023: LTIPs Weighted-Average Weighted-Average LTIPs unvested at December 31, 2022 169,471 $ 19.56 Changes during the period Granted 216,460 $ 20.24 Vested (66,309) $ 19.62 Forfeited or Canceled (94,897) $ 19.82 LTIPs unvested at December 31, 2023 224,725 2.73 $ 20.08 Plan summary In summary, of the 20,100,000 shares of common stock reserved for issuance under the Restated Plan at December 31, 2023, there remain 4,069,349 shares available for future issuance. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS Proposed acquisitions of imaging centers On February 16, 2023, we acquired Houston Medical Imaging, LLC for a purchase consideration of approximately $29.0 million. Houston Medical Imaging consists of seven multi modality imaging centers located in Houston, Texas. On February 1, 2024, we acquired Antelope Valley Outpatient Imaging Center, LLC for a purchase consideration of approximately $3.5 million. Antelope Valley Outpatient Imaging consists of four multi modality imaging centers located in Palmdale, California. |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Pay vs Performance Disclosure | |||
Net income attributable to RadNet, Inc. common stockholders | $ 3,044 | $ 10,650 | $ 24,727 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Dec. 31, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
PRINCIPLES OF CONSOLIDATION | PRINCIPLES OF CONSOLIDATION – The operating activities of subsidiaries are included in the accompanying consolidated financial statements (“financial statements”) from the date of acquisition. Investments in companies in which we have the ability to exercise significant influence, but not control, are accounted for by the equity method. All intercompany transactions and balances, with our consolidated entities and the unsettled amount of intercompany transactions with our equity method investees, have been eliminated in consolidation. As stated in Note 1 above, the Group consists of VIEs and we consolidate the operating activities and balance sheets of each. |
USE OF ESTIMATES | USE OF ESTIMATES - The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates. |
REVENUES | REVENUES – Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to other centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and co-payment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans. |
ACCOUNTS RECEIVABLE | ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. |
SOFTWARE REVENUE RECOGNITION | SOFTWARE REVENUE RECOGNITION – We have developed and sell Picture Archiving Communications Systems (“PACS”) and related services. The PACS sales are made primarily through our sales force and generally include hardware, software, installation, training and first-year warranty support. Hardware which is not unique or special purpose, is purchased from a third-party and resold to customers with a small mark-up. |
SOFTWARE DEVELOPMENT COSTS | SOFTWARE DEVELOPMENT COSTS – When we develop our own software and artificial intelligence solutions we capitalize and amortize those costs over their useful life. Costs related to the research and development of new software products and enhancements to existing software intended for resale to our customers are expensed as incurred. |
CONCENTRATION OF CREDIT RISKS | CONCENTRATION OF CREDIT RISKS – Financial instruments that potentially subject us to credit risk are primarily cash equivalents and accounts receivable. We have placed our cash and cash equivalents with one major financial institution. The cash in the financial institution is in excess of the amount insured by the Federal Deposit Insurance Corporation, or FDIC. Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. We continuously monitor collections and maintain an allowance for bad debts based upon our historical collection experience. In addition, we have notes receivable stemming from our factoring of accounts receivable as stated above. Companies with which we factor our receivables are well known established buyers of such instruments, have agreed to assume the full risk of their collection. |
CASH AND CASH EQUIVALENTS | CASH AND CASH EQUIVALENTS – We consider all highly liquid investments that mature in three months or less when purchased to be cash equivalents. The carrying amount of cash and cash equivalents approximates the fair market value. |
DEFERRED FINANCING COSTS | DEFERRED FINANCING COSTS – Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs are related to our revolving credit facilities. Notes Payable for more information on our revolving lines of credit. |
PROPERTY AND EQUIPMENT | PROPERTY AND EQUIPMENT – Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred. |
BUSINESS COMBINATIONS | BUSINESS COMBINATIONS – When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations. |
GOODWILL AND INDEFINITE LIVED INTANGIBLES | GOODWILL AND INDEFINITE LIVED INTANGIBLESGoodwill, trade name intangibles and IPR&D are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. |
LONG-LIVED ASSETS | LONG-LIVED ASSETS – We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill and indefinite lived intangible assets, for impairment when events or changes indicate the carrying amount of an asset may not be recoverable. Accounting standards requires that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. At December 31, 2023 and December 31, 2021 we recorded lease abandonment of $2.5 million and $7.1 million, respectively in leasehold improvements for facilities that we abandoned. See the Leases discussion below for more information. Other than this, we determined that there were no events or changes in circumstances that indicated our long-lived assets were impaired during any periods presented. |
INCOME TAXES | INCOME TAXES – Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. See Note 10, Income Taxes, for more information. |
LEASES | LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of December 31, 2023. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order. We closely monitor patient levels at our imaging centers and occasionally divest or shut down centers to maximize utilization rates. We may abandon low utilization leases and divert the patients to nearby centers. During 2023, we experienced lower utilization at two imaging centers. To complete the closure of these locations, we took a lease abandonment charge of approximately $5.1 million and $19.7 million at December 31, 2023 and December 31, 2021, respectively. Of these amounts, $2.7 million and $12.6 million were related to right-of-use assets impairment and $2.5 million and $7.1 million were related to the write-off of leasehold improvements for the years ending December 31, 2023 and December 31, 2021. |
UNINSURED RISKS | UNINSURED RISKS – We maintain a high-deductible workers’ compensation insurance policy. We and our affiliated physicians carry an annual medical malpractice insurance policy that protects us for claims that are filed during the policy year and that fall within policy limits. In December 2008, in order to eliminate the exposure for claims not reported during the regular malpractice policy period, we purchased a medical malpractice claims made tail policy, which provides coverage for any claims reported in the event that our medical malpractice policy expires. As of December 31, 2023, this policy remains in effect. |
EMPLOYEE BENEFIT PLAN | EMPLOYEE BENEFIT PLAN – We adopted a profit-sharing/savings plan pursuant to Section 401(k) of the Internal Revenue Code that covers substantially all non-professional employees. Eligible employees may contribute on a tax-deferred basis a percentage of compensation, up to the maximum allowable under tax law. Employee contributions vest immediately. |
EQUITY BASED COMPENSATION | EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated at various points in time: first on April 20, 2015, second on March 9, 2017, third on April 15, 2021 and currently as of April 27, 2023 (the “Restated Plan”). The Restated Plan was most recently approved by our stockholders at our annual stockholders meeting on June 7, 2023. We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We evaluate performance-based awards to determine if it is probable that the vesting conditions will be met. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three five |
FOREIGN CURRENCY TRANSLATION | FOREIGN CURRENCY TRANSLATION – For our operations in Canada, Europe and the United Kingdom, the functional currency of our foreign subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies are translated using the exchange rate at the balance sheet dates. Revenues and expenses are translated using average exchange rates prevailing during the reporting period. Any translation adjustments resulting from this process are shown separately as a |
OTHER COMPREHENSIVE INCOME (LOSS) | OTHER COMPREHENSIVE INCOME (LOSS) – Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in other comprehensive income (loss). The components of other comprehensive income (loss) for the twelve month periods ended December 31, 2023, December 31, 2022, and December 31, 2021 are included in the consolidated statements of comprehensive income. |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected. |
DERIVATIVE INSTRUMENTS | DERIVATIVE INSTRUMENTS |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement: Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data. Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment. The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward SOFR curve in 2023 and forward LIBOR curve in 2022. respectively. The forward SOFR curve and forward LIBOR curve are readily available in the public markets or can be derived from information available in the public markets. Contingent Consideration: The tables below summarize the estimated fair values of contingencies and holdback relating to our acquisitions that are subject to fair value measurements and the classification of these liabilities on our consolidated balance sheets, as follows (in thousands): As of December 31, 2023 Level 1 Level 2 Level 3 Total Accrued expenses and other non-current liabilities Heart & Lung Imaging Limited $ — $ — $ 6,879 $ 6,879 The estimated fair value of these liabilities was determined using Level 3 inputs. For Heart & Lung Imaging Limited, the contingent consideration is determined by the achievement of a specific number of physician reads. As significant inputs for the contingent consideration of Heart & Lung Imaging Limited are not observable and cannot be corroborated by observable market data they are classified as Level 3. As of December 31, 2022 Level 1 Level 2 Level 3 Total Accrued expenses and other non-current liabilities Aidence Holding B.V. milestone consideration $ — $ — $ 11,158 $ 11,158 Quantib B.V. Holdback of 113,303 shares of RadNet common stock $ — $ — $ 3,709 $ 3,709 Montclair Radiological Associates $ — $ — $ 1,200 $ 1,200 Heart & Lung Imaging Limited $ — $ — $ 11,656 $ 11,656 The estimated fair value of these liabilities was determined using Level 3 inputs. For Aidence Holding B.V., the milestone contingent liability was adjusted to fair value based on the yield rate of S&P B-rated corporate bonds and the probability of FDA approval. For the Quantib B.V holdback shares, the fair value was determined by calculating the value of estimated shares issuable as of the reporting date (which was $18.83) translated at the current exchange rate at December 31, 2022, the time period related to the contractual settlement term, and the probability of issuing the shares. For Montclair Radiological Associates the contingent consideration is determined by obtaining specific EBITDA targets within a defined time frame. For Heart & Lung Imaging Limited the contingent consideration is determined by the achievement of a specific number of physician reads. As significant inputs for the contingent consideration of Aidence B.V., Quantib B.V., Montclair Radiological Associates and Heart & Lung Imaging Limited are not observable and cannot be corroborated by observable market data, they are classified as Level 3. The estimated fair values of our long-term debt, which is discussed in Note 8, was determined using Level 2 inputs for the Barclays and Truist term loans. Level 2 inputs primarily relate to comparable market prices. We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, and current liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our finance lease obligations and other notes payable to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates. |
EARNINGS PER SHARE | EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data): |
EQUITY INVESTMENTS AT FAIR VALUE | INVESTMENTS IN EQUITY SECURITIES- Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income. As of December 31, 2023, we have three equity investments for which a fair value is not readily determinable and we do not have significant influence and therefore the total amounts invested are recognized at cost as follows: |
INVESTMENT IN JOINT VENTURES | INVESTMENT IN JOINT VENTURES – We have 13 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, as we do not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of December 31, 2023. |
ACCOUNTING STANDARDS ADOPTED AND ACCOUNTING STANDARDS NOT YET ADOPTED | RECENT ACCOUNTING STANDARDS Recently Issued Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures . The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its consolidated financial position and results of operations. In December 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-09 ("ASU 2023-09"), Income Tax (Topic 740) Improvements to Income Tax Disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and results of operations. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Service Fee Revenue | Our total service fee revenues for the years ended December 31, 2023, 2022, and 2021 are presented in the table below. Our imaging center revenue is displayed as the estimated service fee, broken down by classification of insurance coverage type. Additional revenues are earned from our management services provided to joint ventures and our software and AI subsidiaries. In Thousands 2023 2022 2021 Commercial insurance $ 897,948 $ 785,128 $ 743,462 Medicare 363,863 311,124 280,911 Medicaid 43,175 38,279 34,731 Workers' compensation/personal injury 47,364 51,339 44,235 Other patient revenue 42,249 31,849 19,398 Management fee revenue 17,936 22,235 19,630 Software and teleradiology 18,082 14,238 10,525 Other 20,111 19,428 12,436 Revenue under capitation arrangements 153,433 152,045 148,334 Imaging center segment revenue 1,604,161 1,425,665 1,313,662 AI segment revenue 12,469 4,396 1,415 Total revenue $ 1,616,630 $ 1,430,061 $ 1,315,077 |
Schedule of Accounts Payable and Accrued Expenses | Accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2023 2022 Accounts payable $ 122,888 $ 102,678 Accrued expenses 124,059 181,574 Accrued salary and benefits 71,297 62,072 Accrued professional fees 24,696 23,271 Total $ 342,940 $ 369,595 |
Schedule Of Foreign Currency Translation Amounts | The following is a reconciliation of Foreign Currency Translation amounts for the years ended December 31, 2023, 2022 and 2021 is provided below (in thousands): Currency Translation Balance as of December 31, 2020 (377) Currency Translation Adjustments (65) Balance as of December 31, 2021 (442) Currency Translation Adjustments (3,943) Balance as of December 31, 2022 (4,385) Currency Translation Adjustments 4,617 Balance as of December 31, 2023 232 |
Schedule of Effect of Derivative Instruments on Comprehensive (Loss) Income | A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective in 2020 is as follows (amounts in thousands): Interest Rate Contracts - Ineffective Portion For the twelve months ended Amount of gain (loss) recognized in income on derivative (current period ineffective portion) Location of gain (loss) recognized in Income on derivative (current period ineffective portion) Amount of loss reclassified from accumulated other comprehensive income (loss) into income (prior period effective portion) Location of loss reclassified from accumulated other comprehensive income (loss) into income (prior period effective portion) December 31, 2023 $(8,185) Other Income (Expense) $(3,576) Interest Expense December 31, 2022 $39,621 Other Income (Expense) $(3,687) Interest Expense December 31, 2021 $21,670 Other Income (Expense) $(3,695) Interest Expense |
Schedule of Business Acquisitions by Acquisition, Contingent Consideration | A tabular roll-forward of contingent consideration is as follows (amounts in thousands): For the twelve months ended December 31, 2023 Entity Account January 1, 2023 Balance Settlement of Contingent Consideration Change in Valuation of Contingent Consideration Currency Translation December 31, 2023 Balance Aidence Other Long Term Liabilities $ 11,158 $ (4,000) $ (7,158) $ — $ — Quantib Accrued Expenses & Other Long Term Liabilities $ 3,709 $ (5,110) $ 1,401 $ — $ — Montclair Accrued Expenses $ 1,200 $ (1,200) $ — $ — Heart & Lung Limited Accrued Expenses & Other Long Term Liabilities $ 11,656 $ (7,854) $ 2,477 $ 600 $ 6,879 For the twelve months ended December 31, 2022 Entity Account January 1, 2022 Balance Settlement of Contingent Consideration Change in Valuation of Contingent Consideration Currency Translation December 31, 2022 Balance Aidence Other Long Term Liabilities $ — $ 11,453 $ (362) $ 67 $ 11,158 Quantib Accrued Expenses & Other Long Term Liabilities $ — $ 4,581 $ (903) $ 31 $ 3,709 Montclair Accrued Expenses $ — $ 1,200 $ — $ — $ 1,200 Heart & Lung Limited Accrued Expenses & Other Long Term Liabilities $ — $ 10,814 $ 566 $ 276 $ 11,656 |
Schedule of Fair Value of Assets and Liabilities | The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets in our consolidated balance sheets, as follows (in thousands): As of December 31, 2023 Level 1 Level 2 Level 3 Total Other Current Assets and Deposits and Other 2019 SWAPS - Interest Rate Contracts $ — $ 15,118 $ — $ 15,118 As of December 31, 2022 Level 1 Level 2 Level 3 Total Other Current Assets and Deposits and Other 2019 SWAPS - Interest Rate Contracts $ — $ 23,302 $ — $ 23,302 The tables below summarize the estimated fair values of contingencies and holdback relating to our acquisitions that are subject to fair value measurements and the classification of these liabilities on our consolidated balance sheets, as follows (in thousands): As of December 31, 2023 Level 1 Level 2 Level 3 Total Accrued expenses and other non-current liabilities Heart & Lung Imaging Limited $ — $ — $ 6,879 $ 6,879 The table below summarizes the estimated fair value and carrying amount of our Barclays Term Loans and Trust Term Loan long-term debt as follows (in thousands): As of December 31, 2023 Level 1 Level 2 Level 3 Total Fair Value Total Face Value Barclays Term Loans and Truist Term Loan $ — $ 824,759 $ — $ 824,759 $ 823,063 As of December 31, 2022 Level 1 Level 2 Level 3 Total Fair Value Total Face Value Barclays Term Loans and Truist Term Loan $ — $ 843,594 $ — $ 843,594 $ 864,125 |
Scheulde The Estimated Fair Values | As of December 31, 2022 Level 1 Level 2 Level 3 Total Accrued expenses and other non-current liabilities Aidence Holding B.V. milestone consideration $ — $ — $ 11,158 $ 11,158 Quantib B.V. Holdback of 113,303 shares of RadNet common stock $ — $ — $ 3,709 $ 3,709 Montclair Radiological Associates $ — $ — $ 1,200 $ 1,200 Heart & Lung Imaging Limited $ — $ — $ 11,656 $ 11,656 |
Schedule of Earnings Per Share | Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data): Years Ended December 31, 2023 2022 2021 Net income attributable to RadNet, Inc. common stockholders $ 3,044 $ 10,650 $ 24,727 BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Weighted average number of common shares outstanding during the period 63,580,059 56,293,336 52,496,679 Basic net income per share attributable to RadNet, Inc. common stockholders $ 0.05 $ 0.19 $ 0.47 DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Weighted average number of common shares outstanding during the period 63,580,059 56,293,336 52,496,679 Add nonvested restricted stock subject only to service vesting 202,995 172,139 259,539 Add additional shares issuable upon exercise of stock options, warrants and holdback shares 875,245 855,395 664,815 Weighted average number of common shares used in calculating diluted net income per share 64,658,299 57,320,870 53,421,033 Changes in fair value associated with contingently issuable shares $ — $ (724) $ — Net income attributable to RadNet, Inc's common stockholders for diluted share calculation $3,044 $9,926 $24,727 Diluted net income per share attributable to RadNet, Inc. common stockholders $ 0.05 $ 0.17 $ 0.46 Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive: Shares issuable upon the exercise of stock options 754,131 152,723 47,792 Weight average shares for which the exercise price exceeds the average market price of common stock 70,760 — — |
Schedule of Investment in Joint Ventures | The following table is a summary of our investment in joint ventures during the years ended December 31, 2023 and December 31, 2022 (in thousands): Balance as of December 31, 2021 $ 42,229 Equity contributions in existing and purchase of interest in joint ventures 9,712 Equity in earnings in these joint ventures 10,390 Distribution of earnings (4,438) Balance as of December 31, 2022 $ 57,893 Equity in earnings in these joint ventures 6,427 Equity contributions in existing and purchase of interest in joint ventures 43,993 Distribution of earnings (15,603) Balance as of December 31, 2023 $ 92,710 |
Schedule of Joint Venture Investment and Financial Information | The following table is a summary of key financial data for these joint ventures as of December 31, 2023 and 2022, respectively, and for the years ended December 31, 2023, 2022 and 2021, respectively, (in thousands): December 31, Balance Sheet Data: 2023 2022 Current assets $ 39,819 $ 39,304 Noncurrent assets 224,936 134,694 Current liabilities (46,587) (29,588) Noncurrent liabilities (70,834) (37,952) Total net assets $ 147,334 $ 106,458 2023 2022 2021 Net revenue $ 184,194 $ 145,256 $ 129,023 Net income $ 12,968 $ 21,169 $ 21,893 |
BUSINESS COMBINATIONS AND REL_2
BUSINESS COMBINATIONS AND RELATED ACTIVITY (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Business Acquisitions Acquired Assets and Assumed Liabilities | We made a fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands): 2023: Entity Date Acquired Total Purchase Consideration Property & Equipment Right of Use Assets Goodwill Intangible Assets Other Right of Use Liabilities C.C.D.G.L.R. & S Services Inc.* 1/1/2023 3,500 435 1,689 3,015 50 — (1,689) Southern California Diagnostic Imaging, Inc.* 1/1/2023 1,815 466 1,184 1,272 50 27 (1,184) Inglewood Imaging Center, LLC* 2/1/2023 2,600 877 1,188 1,658 50 15 (1,188) Ramapo Radiology Associates, P.C.* 2/1/2023 2,000 1,663 3,775 229 100 8 (3,775) Madison Radiology Medical Group, Inc.* 4/1/2023 250 100 — 150 — — — Delaware Diagnostic Imaging, P.A.* 8/1/2023 600 401 337 149 50 — (337) Total $10,765 $3,942 $8,173 $6,473 $300 $50 $(8,173) *Fair Value Determination is Final 2022: Entity Date Acquired Total Purchase Consideration Property & Equipment Right of Use Assets Goodwill Intangible Assets Other Right of Use Liabilities IFRC LLC*^ 1/1/2022 8,200 2,910 1,703 5,271 — 19 (1,703) IFRC LLC*^ 1/1/2022 4,800 2,103 857 2,697 — — (857) Montclair Radiological Associates, P.A.*# 10/1/2022 94,877 16,414 4,665 79,690 400 (2,168) (4,124) Heart & Lung Imaging Limited+ 11/1/2022 32,000 — — 16,200 15,800 — — Chelsea Diagnostic Radiology, P.C.* 12/1/2022 2,800 568 — 2,132 100 — — North Jersey Imaging Center, LLC* 12/9/2022 104 20 — 55 25 4 — Total $142,781 $22,015 $7,225 $106,045 $16,325 $(2,145) $(6,684) *Fair Value Determination is Final ^ IFRC LLC acquisitions consisted of three subsidiaries of IFRC, one of which was purchased separately by a joint venture with Calvert Medical Imaging Centers, LLC. # Montclair Radiological Associates includes a liability for $1.2 million in contingent consideration. |
SEGMENT REPORTING (Tables)
SEGMENT REPORTING (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information, by Segment | Twelve Months Ended December 31, 2023 Imaging Centers AI Intersegment Elimination Consolidated Total Revenue: Third Party $ 1,610,707 $ 5,923 $ — $ 1,616,630 Intersegment — 6,546 (6,546) — Total revenue $ 1,610,707 $ 12,469 $ (6,546) $ 1,616,630 Twelve Months Ended December 31, 2022 Imaging Centers AI Intersegment Elimination Consolidated Total Revenue: Third Party $ 1,425,665 $ 4,396 $ — $ 1,430,061 Intersegment — — — — Total revenue $ 1,425,665 $ 4,396 $ — $ 1,430,061 The table below present segment information reconciled to our financial results, with segment operating income or loss including revenue less cost of operations, depreciation and amortization, and other operating expenses to the extent specifically identified by segment (in thousands): Twelve Months Ended December 31, 2023 2022 2021 Revenue: Imaging Centers $ 1,604,161 $ 1,425,665 $ 1,313,662 AI 12,469 4,396 1,415 Total revenue $ 1,616,630 $ 1,430,061 $ 1,315,077 Cost of Operations Imaging Centers $ 1,371,036 $ 1,240,593 $ 1,117,941 AI 24,203 23,753 5,333 Total cost of operations $ 1,395,239 $ 1,264,346 $ 1,123,274 Gain on contribution of imaging centers into joint venture Imaging Centers $ (16,808) $ — $ — AI — — — Total cost of operations $ (16,808) $ — $ — Lease abandonment charges Imaging Centers $ 5,146 $ — $ 19,675 AI — — — Total depreciation and amortization $ 5,146 $ — $ 19,675 Depreciation and Amortization Imaging Centers $ 120,776 $ 109,524 $ 96,174 AI 7,615 6,353 520 Total depreciation and amortization $ 128,391 $ 115,877 $ 96,694 Loss on Disposal of Equipment Imaging Centers $ 2,191 $ 2,506 $ 1,246 AI (4) 23 — Total loss (gain) $ 2,187 $ 2,529 $ 1,246 Severance Imaging Centers $ 1,973 $ 926 $ 744 AI 1,805 20 — Total severance $ 3,778 $ 946 $ 744 Income from Operations Imaging Centers $ 119,847 $ 72,116 $ 77,882 AI (21,150) (25,753) (4,438) Total income from operations $ 98,697 $ 46,363 $ 73,444 |
GOODWILL AND OTHER INTANGIBLE_2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill and Other Intangible Assets | The following is a reconciliation of Goodwill by business segment for the years ended December 31, 2022 and December 31, 2023 is provided below (in thousands): Imaging Center Artificial Intelligence Total Balance as of December 31, 2021 $ 489,210 $ 24,610 $ 513,820 Additions 120,551 48,697 169,248 Disposals (4,200) — (4,200) Measurement period and other adjustments (106) 147 41 Currency translation 1,028 (2,272) (1,244) Balance as of December 31, 2022 $ 606,483 $ 71,182 $ 677,665 Additions 6,473 — 6,473 Disposals (9,235) — (9,235) Measurement period and other adjustments 1,603 — 1,603 Currency translation 1,233 1,724 2,957 Balance as of December 31, 2023 $ 606,557 $ 72,906 $ 679,463 |
Schedule of Annual Amortization Expense | The following tables shows annual amortization expense, by asset classes that will be recorded over the next five years (in thousands): 2024 2025 2026 2027 2028 Thereafter Total Weighted average amortization period remaining in years Management Service Contracts $ 2,287 $ 2,287 $ 2,287 $ 2,287 $ 2,287 $ 6,671 $ 18,106 7.9 Covenant not to compete and other contracts 946 714 427 132 45 6 2,270 3.4 Customer Relationships 1,234 1,104 981 797 764 10,564 15,444 17.7 Patent and Trademarks 316 316 316 315 300 164 1,727 5.8 Developed Technology & Software 7,785 7,785 7,745 7,210 7,046 6,117 43,688 5.7 Trade Names amortized 77 77 77 77 63 27 398 5.3 Trade Names indefinite life — — — — — 7,100 7,100 — IPR&D — — — — — 1,882 1,882 — Total Annual Amortization $ 12,645 $ 12,283 $ 11,833 $ 10,818 $ 10,505 $ 32,531 $ 90,615 |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | Property and equipment and accumulated depreciation and amortization are as follows (in thousands): December 31, 2023 2022 Land $ 250 $ 250 Medical equipment 714,400 649,034 Computer and office equipment, furniture and fixtures 127,540 119,467 Software costs 47,286 36,015 Leasehold improvements 537,853 501,963 Equipment originally acquired under finance/capital lease 13,971 13,971 Total property and equipment cost 1,441,300 1,320,700 Accumulated depreciation (836,899) (754,739) Total property and equipment $ 604,401 $ 565,961 |
CREDIT FACILITIES AND NOTES P_2
CREDIT FACILITIES AND NOTES PAYABLE (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Revolving Credit Facility, Notes Payable, and Capital Lease Obligations | As of December 31, 2023 and December 31, 2022 our term loan debt and other obligations consisted of the following (in thousands): December 31, 2023 December 31, 2022 Barclays Term Loans collateralized by RadNet's tangible and intangible assets $ 678,687 $ 714,125 Discount on Barclays Term Loans (9,041) (11,127) Truist Term Loan collateralized by NJIN's tangible and intangible assets 144,375 150,000 Discount on Truist Term Loan (990) (1,254) Equipment notes payable at 6.0%, due 2028, collateralized by medical equipment 17,011 — Total debt obligations 830,042 851,744 Less current portion (17,974) (12,400) Long-term portion of debt obligations $ 812,068 $ 839,344 |
Schedule of Annual Principal Maturities of Notes Payable | The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities for years ending December 31 (in thousands) 2024 $ 20,324 2025 22,431 2026 22,676 2027 124,188 2028 650,454 Total notes payable obligations $ 840,073 |
Schedule of Leverage Ratio | All obligations under the Truist Restated Credit Agreement bear interest at either a SOFR or a Base Rate (each as defined in the Truist Restated Credit Agreement), plus an applicable margin according to the following schedule: Pricing Level Leverage Ratio Applicable Margin for SOFR Loans Applicable Margin for Base Rate Loans Applicable Margin for Letter of Credit Fees Applicable Percentage for Commitment Fee I Greater than or equal to 3.00:1.00 2.50% per annum 1.50% per annum 2.50% per annum 0.45% per annum II Less than 3.00:1.00 but greater than or equal to 2.50:1.00 2.25% per annum 1.25% per annum 2.25% per annum 0.40% per annum III Less than 2.50:1.00 but greater than or equal to 2.00:1.00 2.00% per annum 1.00% per annum 2.00% per annum 0.35% per annum IV Less than 2.00:1.00 but greater than or equal to 1.50:1.00 1.75% per annum 0.75% per annum 1.75% per annum 0.30% per annum V Less than 1.50:1.00 1.50% per annum 0.50% per annum 1.50% per annum 0.30% per annum Revolving loans borrowed under the Barclays Revolving Credit Facility bear interest at either a SOFR or an Alternate Base Rate (in each case, as defined in the Barclays Restated Credit Agreement) plus an applicable margin which adjusts depending on our net leverage ratio, according to the following schedule: Net Leverage Ratio Term SOFR Loans Alternative Base Rate Spread > 3.50x 3.25% 2.25% > 3.00x but ≤ 3.50x 3.00% 2.00% ≤ 3.00x 2.75% 1.75% |
LEASES (Tables)
LEASES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Schedule of Lease, Cost | The components of lease expense were as follows: Years ended December 31, (In thousands) 2023 2022 2021 Operating lease cost (1) $ 106,954 $ 107,475 $ 121,578 Finance lease cost: Depreciation of leased equipment $ 1,204 $ 2,896 $ 3,068 Interest on lease liabilities — — 46 Total finance lease cost $ 1,204 $ 2,896 $ 3,114 1) Operating lease cost above for the year ended December 31, 2023 and 2021 included $2.7 million and $12.6 million, respectively in lease abandonment charges. Please see our discussion in the Leases section of Note 2, Summary of Significant Accounting Policies. |
Schedule of Cash Flow, Supplemental Disclosures | Supplemental cash flow information related to leases was as follows: Years ended December 31, (In thousands) 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 101,516 $ 108,004 $ 110,288 Operating cash flows from financing leases — — 46 Financing cash flows from financing leases — — 3,304 Right-of-use & Equipment assets obtained in exchange for lease obligations: Operating leases 55,852 88,080 186,695 |
Schedule of Assets and Liabilities Lessee | Supplemental balance sheet information related to leases was as follows: (In thousands, except lease term and discount rates) December 31, 2023 2022 Operating Leases Operating lease right-of-use assets $ 596,032 $ 603,524 Current portion of operating lease liability 55,981 57,607 Long-term operating lease liability 605,097 604,117 Total operating lease liabilities $ 661,078 $ 661,724 Finance Leases Equipment at cost $ 13,971 $ 13,971 Accumulated depreciation (13,374) (12,171) Equipment, net $ 597 $ 1,801 Weighted Average Remaining Lease Term Operating leases - years 10.6 10.9 Weighted Average Discount Rate Operating leases 6.7 % 6.4 % |
Schedule of Maturities of Operating Lease Liability | Maturities of lease liabilities were as follows: (In thousands) Operating Leases Year Ending December 31, 2024 $ 97,603 2025 $ 92,092 2026 91,400 2027 88,977 2028 85,633 Thereafter 482,594 Total Lease Payments 938,299 Less imputed interest (277,221) Total $ 661,078 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income before Income Tax, Domestic and Foreign | For the years ended December 31, 2023, 2022 and 2021, we have the following income (loss) before income taxes (in thousands): December 31, 2023 2022 2021 US Domestic $ 60,374 $ 59,529 $ 58,806 Foreign (21,564) (16,560) 73 Income (loss) before income taxes $ 38,810 $ 42,969 $ 58,879 |
Schedule of Components of Income Tax Expense | For the years ended December 31, 2023, 2022 and 2021, we recognized income tax expense comprised of the following (in thousands): December 31, 2023 2022 2021 Federal current tax $ — $ — $ — State current tax 3,442 371 (2,191) Foreign current tax 638 87 18 Other current tax — — — Federal deferred tax 8,960 6,470 9,831 State deferred tax (2,724) 5,863 6,902 Foreign deferred tax (1,843) (3,430) — Currency translation — — — Income tax expense 8,473 9,361 14,560 |
Schedule of Reconciliation of Income Tax Expense | A reconciliation of the statutory U.S. federal rate and effective rates is as follows: Years Ended December 31, 2023 2022 2021 Federal tax $ 8,150 $ 9,023 $ 12,365 State franchise tax, net of federal benefit 3,730 595 4,198 Other Non deductible expenses 196 305 (93) Officer Compensation 1,199 759 291 Noncontrolling interests in partnerships (5,752) (4,821) (4,114) Changes in valuation allowance (2,569) 6,124 (249) Return to provision 5,987 234 (2,530) Deferred true-ups and other 483 (1,451) 5,009 Foreign rate differential (1,083) (737) 4 Uncertain tax provisions (884) (749) (321) Tax rate adjustment (984) — — Other differences — 79 — Income tax expense $ 8,473 $ 9,361 $ 14,560 |
Schedule of Deferred Tax Assets and Liabilities | Our deferred tax assets and liabilities comprise the following (in thousands): December 31, Deferred tax assets: 2023 2022 Net operating losses $ 43,247 $ 68,124 Accrued expenses 4,432 3,941 Operating lease liability 136,097 142,347 Equity compensation 4,179 4,387 Allowance for doubtful accounts 2,198 3,071 Other 15,755 6,541 Valuation allowance (9,688) (12,095) Total Deferred Tax Assets $ 196,220 $ 216,316 Deferred tax liabilities: Property and equipment (7,851) (9,214) Goodwill (42,419) (38,820) Intangibles (15,578) (18,640) Operating lease right-of-use asset (122,840) (129,802) Outside basis difference (18,547) (20,015) Other (4,761) (9,081) Total Deferred Tax Liabilities $ (211,996) $ (225,572) Net Deferred Tax Liability $ (15,776) $ (9,256) |
Schedule of Unrecognized Tax Benefits | A reconciliation of the total gross amounts of unrecognized tax benefits for the years ended are as follows (in thousands): December 31, 2023 2022 2021 Balance at beginning of year $ 4,144 $ 5,088 $ 5,484 Increases related to prior year tax positions 54 55 317 Increases related to current year tax positions 62 — — Expiration of the statute of limitations for the assessment of taxes (1,180) (999) (713) Increase related to change in rate 2 — — Balance at end of year $ 3,082 $ 4,144 $ 5,088 |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Options Activity | The following summarizes all of our option transactions for the twelve months ended December 31, 2023: Outstanding Options Shares Weighted Average Weighted Average Aggregate Balance, December 31, 2022 678,914 $ 15.72 Granted 261,220 18.64 Exercised (12,723) 11.11 Canceled, forfeited or expired (16,000) 17.06 Balance, December 31, 2023 911,411 16.60 6.22 $ 16,561,659 Exercisable at December 31, 2023 668,809 14.75 5.24 13,387,921 Outstanding Options Shares Weighted Average Weighted Average Aggregate Balance, December 31, 2022 116,982 Exercised (37,909) — Balance, December 31, 2023 79,073 — 5.75 $ 2,749,368 Exercisable at December 31, 2023 76,612 — 5.75 2,663,803 |
Schedule of RSA Activity | The following summarizes all unvested RSA’s activities during the twelve months ended December 31, 2023: RSA's Weighted-Average Weighted-Average RSA's unvested at December 31, 2022 536,767 $ 23.84 Changes during the period Granted 825,255 $ 21.31 Vested (785,656) $ 22.12 Forfeited (39,008) $ 18.31 RSA's unvested at December 31, 2023 537,358 0.90 $ 22.99 |
Schedule of LTIPs | The following summarizes all unvested AI LTIPs activities during the twelve months ended December 31, 2023: LTIPs Weighted-Average Weighted-Average LTIPs unvested at December 31, 2022 169,471 $ 19.56 Changes during the period Granted 216,460 $ 20.24 Vested (66,309) $ 19.62 Forfeited or Canceled (94,897) $ 19.82 LTIPs unvested at December 31, 2023 224,725 2.73 $ 20.08 |
NATURE OF BUSINESS (Details )
NATURE OF BUSINESS (Details ) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Jun. 30, 2023 shares | Dec. 31, 2023 USD ($) loan center $ / shares | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] | ||||
Number of centers | center | 366 | |||
Number of reportable segments | loan | 2 | |||
BRMG and NY Groups revenues | $ 205,600 | $ 189,100 | $ 179,600 | |
BRMG and NY Groups operating expenses | 205,600 | 189,100 | 179,600 | |
Management services provided to BRMG and NY Groups | 849,400 | 786,500 | 749,200 | |
BRMG and NY Groups accounts receivable | 2,690,473 | 2,433,907 | ||
BRMG and NY Groups accounts payable | 1,877,114 | 1,942,455 | ||
Expenses from transactions with related party | $ 1,395,239 | 1,264,346 | $ 1,123,274 | |
Common Stock | Public Offering | ||||
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] | ||||
Number of shares issued in transaction (in shares) | shares | 8,711,250 | |||
Stock price (in dollars per share) | $ / shares | $ 29.75 | |||
Gross proceeds | $ 259,200 | |||
Public offering expenses | 13,400 | |||
Variable Interest Entity, Primary Beneficiary | ||||
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] | ||||
BRMG and NY Groups accounts receivable | 94,100 | 110,300 | ||
BRMG and NY Groups accounts payable | $ 16,700 | $ 16,200 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Net Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue from External Customer [Line Items] | |||
Service fee revenue | $ 1,616,630 | $ 1,430,061 | $ 1,315,077 |
Imaging center segment revenue | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 1,604,161 | 1,425,665 | 1,313,662 |
Commercial insurance | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 897,948 | 785,128 | 743,462 |
Medicare | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 363,863 | 311,124 | 280,911 |
Medicaid | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 43,175 | 38,279 | 34,731 |
Workers' compensation/personal injury | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 47,364 | 51,339 | 44,235 |
Other patient revenue | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 42,249 | 31,849 | 19,398 |
Management fee revenue | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 17,936 | 22,235 | 19,630 |
Software and teleradiology | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 18,082 | 14,238 | 10,525 |
Other | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 20,111 | 19,428 | 12,436 |
Revenue under capitation arrangements | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | 153,433 | 152,045 | 148,334 |
AI segment revenue | |||
Revenue from External Customer [Line Items] | |||
Service fee revenue | $ 12,469 | $ 4,396 | $ 1,415 |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information1 (Details) - USD ($) $ in Millions | 24 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | |
Property, Plant and Equipment [Line Items] | |||
Factoring receivable | $ 14.3 | $ 15.4 | |
C O V I D19 Pandemic | |||
Property, Plant and Equipment [Line Items] | |||
Advance medicare payments | $ 39.6 |
SUMMARY OF SIGNIFICANT ACCOUN_6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Accounting Policies [Abstract] | ||
Accounts payable | $ 122,888 | $ 102,678 |
Accrued expenses | 124,059 | 181,574 |
Accrued salary and benefits | 71,297 | 62,072 |
Accrued professional fees | 24,696 | 23,271 |
Total | $ 342,940 | $ 369,595 |
SUMMARY OF SIGNIFICANT ACCOUN_7
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information2 (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | |||
Service fee revenue | $ 1,616,630 | $ 1,430,061 | $ 1,315,077 |
Deferred financing costs, net of accumulated amortization | $ 1,600 | 2,300 | |
Minimum | Propery and equipment, net | |||
Property, Plant and Equipment [Line Items] | |||
PP&E useful life | 3 years | ||
Minimum | Leasehold improvements | |||
Property, Plant and Equipment [Line Items] | |||
PP&E useful life | 3 years | ||
Maximum | Propery and equipment, net | |||
Property, Plant and Equipment [Line Items] | |||
PP&E useful life | 15 years | ||
Maximum | Leasehold improvements | |||
Property, Plant and Equipment [Line Items] | |||
PP&E useful life | 15 years | ||
Patient Services, Net [Member] | eRAD | |||
Property, Plant and Equipment [Line Items] | |||
Service fee revenue | $ 20,200 | $ 13,200 | $ 10,500 |
SUMMARY OF SIGNIFICANT ACCOUN_8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information3 (Details) - USD ($) | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2021 | Dec. 31, 2022 | Jan. 20, 2022 | |
Property, Plant and Equipment [Line Items] | ||||
Goodwill | $ 679,463,000 | $ 513,820,000 | $ 677,665,000 | |
Indefinite lived intangible assets | 9,000,000 | 24,100,000 | ||
Lease abandonment charges | 5,100,000 | 19,700,000 | ||
Workers' compensation liability, current | 3,400,000 | 3,900,000 | ||
Medical malpractice deductible per incidence | 10,000 | |||
Blue Shield | Minimum | ||||
Property, Plant and Equipment [Line Items] | ||||
Stop loss policy claim amount | 250,000 | |||
Blue Shield | Maximum | ||||
Property, Plant and Equipment [Line Items] | ||||
Stop loss policy claim amount | 1,000,000 | |||
Reinsurance Policy, Type [Axis]: Health Insurance Member | ||||
Property, Plant and Equipment [Line Items] | ||||
Self-insurance accrual | 7,200,000 | $ 7,400,000 | ||
Leasehold improvements | ||||
Property, Plant and Equipment [Line Items] | ||||
Impairment of long lived asset | 2,500,000 | 7,100,000 | ||
Impairment loss | 2,700,000 | $ 12,600,000 | ||
Aidence | ||||
Property, Plant and Equipment [Line Items] | ||||
Goodwill | $ 22,900,000 | |||
Impairment of intangible assets | $ 3,900,000 |
SUMMARY OF SIGNIFICANT ACCOUN_9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information4 (Details) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 USD ($) incentivePlan | Dec. 31, 2022 USD ($) | Apr. 15, 2021 shares | |
Property, Plant and Equipment [Line Items] | |||
Employer matching contribution, percent | 1% | ||
Employee contribution, percent | 4% | ||
Expected employee contribution | $ | $ 0 | $ 3 | |
Number of plans | incentivePlan | 1 | ||
Shares authorized | shares | 20,100,000 | ||
Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Share-based payment award, award vesting period | 1 year | ||
Share-based payment award, expiration period | 5 years | ||
Minimum | Restated Plan | |||
Property, Plant and Equipment [Line Items] | |||
Share-based payment award, award vesting period | 3 years | ||
Share-based payment award, expiration period | 5 years | ||
Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Share-based payment award, award vesting period | 5 years | ||
Share-based payment award, expiration period | 10 years | ||
Maximum | Restated Plan | |||
Property, Plant and Equipment [Line Items] | |||
Share-based payment award, award vesting period | 5 years | ||
Share-based payment award, expiration period | 10 years |
SUMMARY OF SIGNIFICANT ACCOU_10
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Foreign Currency Translation (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Currency Translation | |||
Beginning Balance | $ (4,385) | $ (442) | $ (377) |
Currency Translation Adjustments | 4,617 | (3,943) | (65) |
Ending Balance | $ 232 | $ (4,385) | $ (442) |
SUMMARY OF SIGNIFICANT ACCOU_11
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information5 (Details) | 24 Months Ended | 40 Months Ended | ||||
Oct. 31, 2025 USD ($) | Oct. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Jul. 01, 2020 USD ($) | Jun. 30, 2019 USD ($) agreement | |
Property, Plant and Equipment [Line Items] | ||||||
Accumulated other comprehensive income | $ 630,695,000 | $ 332,995,000 | ||||
Monthly amortization of deferred hedge gains | $ 400,000 | |||||
Forecast | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Monthly amortization of deferred hedge gains | $ 300,000 | |||||
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Accumulated other comprehensive income | $ 24,400,000 | |||||
2019 SWAPS | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Number of forward interest rate cap agreements | agreement | 4,000 | |||||
Notional amounts | $ 500,000,000 | |||||
2019 SWAPS | 2019 swaps | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Notional amounts | $ 100,000,000 | |||||
2019 SWAPS | 2019 swaps | London Interbank Offered Rate (LIBOR) | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Basis spread on variable rate | 1.89% | |||||
2019 SWAPS | October 2023 | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Number of forward interest rate cap agreements | agreement | 2 | |||||
Notional amounts | $ 50,000,000 | |||||
2019 SWAPS | October 2025 | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Number of forward interest rate cap agreements | agreement | 2 | |||||
Notional amounts | $ 200,000,000 | |||||
2019 SWAPS1 | 2019 swaps | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Notional amounts | $ 400,000,000 | |||||
2019 SWAPS1 | 2019 swaps | London Interbank Offered Rate (LIBOR) | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Basis spread on variable rate | 1.98% |
SUMMARY OF SIGNIFICANT ACCOU_12
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Derivatives (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Offsetting Assets [Line Items] | |||
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Interest expense | Interest expense | Interest expense |
Change in fair value of cash flow hedge from prior periods reclassified to earnings | $ (3,576) | $ (3,687) | $ (3,695) |
2019 swaps | |||
Offsetting Assets [Line Items] | |||
Amount of gain (loss) recognized in income on derivative (current period ineffective portion) | (8,185) | 39,621 | 21,670 |
2019 swaps | Interest Expense | |||
Offsetting Assets [Line Items] | |||
Change in fair value of cash flow hedge from prior periods reclassified to earnings | $ (3,576) | $ (3,687) | $ (3,695) |
SUMMARY OF SIGNIFICANT ACCOU_13
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information6 (Details) $ in Thousands | 1 Months Ended | 12 Months Ended | |||||||||
Dec. 12, 2023 USD ($) shares | Jul. 07, 2023 USD ($) shares | Apr. 13, 2023 shares | Nov. 01, 2022 USD ($) shares | Jan. 20, 2022 USD ($) loan shares | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Sep. 20, 2023 USD ($) shares | Oct. 01, 2022 USD ($) | |
Property, Plant and Equipment [Line Items] | |||||||||||
Change in value of contingent consideration | $ (3,880) | $ (325) | $ 0 | ||||||||
Contingent consideration | 5,495 | 0 | 0 | ||||||||
Aidence | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Purchase agreements | $ 10,000 | ||||||||||
Number of identified milestones | loan | 2 | ||||||||||
Contingent consideration to guarantee share value issued | $ 11,900 | 0 | 11,158 | 0 | |||||||
Change in value of contingent consideration | (7,158) | (362) | |||||||||
Shares issued (in shares) | shares | 359,002 | 1,141,234 | |||||||||
Aidence | Contingent Milestone Consideration | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | $ 7,400 | 7,200 | |||||||||
Change in value of contingent consideration | 7,200 | ||||||||||
Aidence | Cash Holdback | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | $ 4,500 | 4,000 | |||||||||
Aidence Holding B.V. milestone consideration | General Holdback | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Shares issued (in shares) | shares | 144,227 | ||||||||||
Quantib | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | 0 | 3,709 | 0 | ||||||||
Change in value of contingent consideration | 1,401 | (903) | |||||||||
Shares issued (in shares) | shares | 965,058 | ||||||||||
Business combination, contingent consideration, liability, period | 18 months | ||||||||||
Business acquisition, equity interest issued or issuable, additional number of shares | shares | 113,303 | ||||||||||
Business acquisition, equity interest issued or issuable, fair value of additional shares issued after execution | $ 3,000 | ||||||||||
Quantib | Contingent Milestone Consideration | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration | $ 2,100 | ||||||||||
Quantib | Cash Holdback | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | $ 1,600 | 1,600 | |||||||||
Quantib | General Holdback | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | 1,600 | ||||||||||
Quantib | Stock Holdback | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | $ 3,500 | ||||||||||
Shares issued (in shares) | shares | 113,303 | ||||||||||
Business acquisition, equity interest issued or issuable, additional number of shares | shares | 113,303 | ||||||||||
Montclair | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | 0 | 1,200 | 0 | $ 1,200 | |||||||
Change in value of contingent consideration | $ (1,200) | 0 | |||||||||
Heart & Lung Imaging Limited | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | $ 10,800 | 6,879 | 11,656 | $ 0 | |||||||
Change in value of contingent consideration | 2,477 | 566 | |||||||||
Shares issued (in shares) | shares | 359,002 | ||||||||||
Business combination, contingent consideration, liability, period | 24 months | ||||||||||
Business acquisition, percentage of voting interests acquired | 75% | ||||||||||
Heart & Lung Imaging Limited | Contingent Milestone Consideration | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | $ 10,200 | $ 6,200 | $ 11,100 | $ 1,600 | |||||||
Business acquisition, equity interest issued or issuable, additional number of shares | shares | 56,600 | ||||||||||
Contingent consideration settlement | $ 1,800 | ||||||||||
Issuance of common stock for acquisitions (in shares) | shares | 64,569 | ||||||||||
Issuance of common stock for acquisitions | $ 2,300 | ||||||||||
Heart & Lung Imaging Limited | Cash Holdback | |||||||||||
Property, Plant and Equipment [Line Items] | |||||||||||
Contingent consideration to guarantee share value issued | $ 600 |
SUMMARY OF SIGNIFICANT ACCOU_14
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Contingent Consideration (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Business Combination, Contingent Consideration, Liability [Roll Forward] | ||||
Change in Valuation of Contingent Consideration | $ (3,880) | $ (325) | $ 0 | |
Aidence | ||||
Business Combination, Contingent Consideration, Liability [Roll Forward] | ||||
Beginning balance | 11,158 | 0 | ||
Settlement of Contingent Consideration | (4,000) | 11,453 | ||
Change in Valuation of Contingent Consideration | (7,158) | (362) | ||
Currency Translation | 0 | 67 | ||
Ending balance | 0 | 11,158 | 0 | |
Quantib | ||||
Business Combination, Contingent Consideration, Liability [Roll Forward] | ||||
Beginning balance | 3,709 | 0 | ||
Settlement of Contingent Consideration | (5,110) | 4,581 | ||
Change in Valuation of Contingent Consideration | 1,401 | (903) | ||
Currency Translation | 0 | 31 | ||
Ending balance | 0 | 3,709 | 0 | |
Montclair | ||||
Business Combination, Contingent Consideration, Liability [Roll Forward] | ||||
Beginning balance | 1,200 | 0 | ||
Settlement of Contingent Consideration | 1,200 | |||
Change in Valuation of Contingent Consideration | $ (1,200) | 0 | ||
Currency Translation | 0 | 0 | ||
Ending balance | 0 | 1,200 | 0 | |
Heart & Lung Imaging Limited | ||||
Business Combination, Contingent Consideration, Liability [Roll Forward] | ||||
Beginning balance | 11,656 | 0 | ||
Settlement of Contingent Consideration | (7,854) | 10,814 | ||
Change in Valuation of Contingent Consideration | 2,477 | 566 | ||
Currency Translation | 600 | 276 | ||
Ending balance | $ 6,879 | $ 11,656 | $ 0 |
SUMMARY OF SIGNIFICANT ACCOU_15
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Jan. 20, 2022 |
Accrued expenses and other non-current liabilities | |||
Value of estimated shares issuable | $ 18.83 | ||
Quantib B.V. | |||
Accrued expenses and other non-current liabilities | |||
Business acquisition, equity interest issued or issuable, additional number of shares | 113,303 | ||
Estimate of Fair Value Measurement | Aidence | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | $ 11,158 | ||
Estimate of Fair Value Measurement | Quantib B.V. | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 3,709 | ||
Estimate of Fair Value Measurement | Montclair | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 1,200 | ||
Estimate of Fair Value Measurement | Heart & Lung Imaging Limited | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | $ 6,879 | 11,656 | |
Estimate of Fair Value Measurement | 2019 swaps | |||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Other Current Assets and Deposits and Other | 15,118 | ||
Other Current Assets and Deposits and Other | 23,302 | ||
Estimate of Fair Value Measurement | Level 1 | Aidence | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | ||
Estimate of Fair Value Measurement | Level 1 | Quantib B.V. | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | ||
Estimate of Fair Value Measurement | Level 1 | Montclair | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | ||
Estimate of Fair Value Measurement | Level 1 | Heart & Lung Imaging Limited | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | 0 | |
Estimate of Fair Value Measurement | Level 1 | 2019 swaps | |||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Other Current Assets and Deposits and Other | 0 | ||
Other Current Assets and Deposits and Other | 0 | ||
Estimate of Fair Value Measurement | Level 2 | Aidence | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | ||
Estimate of Fair Value Measurement | Level 2 | Quantib B.V. | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | ||
Estimate of Fair Value Measurement | Level 2 | Montclair | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | ||
Estimate of Fair Value Measurement | Level 2 | Heart & Lung Imaging Limited | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 0 | 0 | |
Estimate of Fair Value Measurement | Level 2 | 2019 swaps | |||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Other Current Assets and Deposits and Other | 15,118 | ||
Other Current Assets and Deposits and Other | 23,302 | ||
Estimate of Fair Value Measurement | Level 3 | Aidence | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 11,158 | ||
Estimate of Fair Value Measurement | Level 3 | Quantib B.V. | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 3,709 | ||
Estimate of Fair Value Measurement | Level 3 | Montclair | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 1,200 | ||
Estimate of Fair Value Measurement | Level 3 | Heart & Lung Imaging Limited | |||
Accrued expenses and other non-current liabilities | |||
Business combination, contingent consideration | 6,879 | 11,656 | |
Estimate of Fair Value Measurement | Level 3 | 2019 swaps | |||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Other Current Assets and Deposits and Other | $ 0 | ||
Other Current Assets and Deposits and Other | $ 0 |
SUMMARY OF SIGNIFICANT ACCOU_16
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Debt (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Barclays Term Loans and Truist Term Loan | $ 823,063,000 | $ 864,125,000 |
Barclays | ||
Property, Plant and Equipment [Line Items] | ||
Total credit facilities outstanding | 0 | 0 |
Truist | ||
Property, Plant and Equipment [Line Items] | ||
Total credit facilities outstanding | 0 | 0 |
Estimate of Fair Value Measurement | ||
Property, Plant and Equipment [Line Items] | ||
Barclays Term Loans and Truist Term Loan | 824,759,000 | 843,594,000 |
Level 1 | Estimate of Fair Value Measurement | ||
Property, Plant and Equipment [Line Items] | ||
Barclays Term Loans and Truist Term Loan | 0 | 0 |
Level 2 | Estimate of Fair Value Measurement | ||
Property, Plant and Equipment [Line Items] | ||
Barclays Term Loans and Truist Term Loan | 824,759,000 | 843,594,000 |
Level 3 | Estimate of Fair Value Measurement | ||
Property, Plant and Equipment [Line Items] | ||
Barclays Term Loans and Truist Term Loan | $ 0 | $ 0 |
SUMMARY OF SIGNIFICANT ACCOU_17
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | |||
Net income attributable to RadNet, Inc. common stockholders | $ 3,044 | $ 10,650 | $ 24,727 |
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | |||
Weighted average number of common shares outstanding during the period (in shares) | 63,580,059 | 56,293,336 | 52,496,679 |
Basic net income per share attributable to RadNet, Inc. common stockholders (in dollars per share) | $ 0.05 | $ 0.19 | $ 0.47 |
DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | |||
Weighted average number of common shares outstanding during the period (in shares) | 63,580,059 | 56,293,336 | 52,496,679 |
Add nonvested restricted stock subject only to service vesting (in shares) | 202,995 | 172,139 | 259,539 |
Add additional shares issuable upon exercise of stock options, warrants and holdback shares (in shares) | 875,245 | 855,395 | 664,815 |
Weighted average number of common shares used in calculating diluted net income per share (in shares) | 64,658,299 | 57,320,870 | 53,421,033 |
Changes in fair value associated with contingently issuable shares | $ 0 | $ (724) | $ 0 |
Net income attributable to RadNet, Inc's common stockholders for diluted share calculation | $ 3,044 | $ 9,926 | $ 24,727 |
Diluted net income per share attributable to RadNet, Inc. common stockholders (in dollars per share) | $ 0.05 | $ 0.17 | $ 0.46 |
Shares issuable upon the exercise of stock options | |||
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive: | |||
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares) | 754,131 | 152,723 | 47,792 |
Weight average shares for which the exercise price exceeds the average market price of common stock | |||
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive: | |||
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares) | 70,760 | 0 | 0 |
SUMMARY OF SIGNIFICANT ACCOU_18
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information7 (Details) $ / shares in Units, $ in Thousands | 12 Months Ended | |||||
Nov. 05, 2019 USD ($) shares | Feb. 01, 2018 USD ($) shares | Dec. 31, 2023 USD ($) investment jointVenture | Oct. 06, 2023 $ / shares shares | Oct. 11, 2019 shares | Jan. 01, 2019 USD ($) | |
Property, Plant and Equipment [Line Items] | ||||||
Number of investments | investment | 3 | |||||
Number of unconsolidated joint ventures | jointVenture | 13 | |||||
Dignity Health | Minimum | Joint Venture | Glendale Advanced Imaging | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Economic interest | 35% | |||||
Dignity Health | Maximum | Joint Venture | Glendale Advanced Imaging | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Economic interest | 55% | |||||
Series C Preferred Stock | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Preferred stock (in shares ) | shares | 20,325,203 | |||||
Exchange rate In dollars per share) | $ / shares | $ 0.123 | |||||
Medic Vision | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Total net assets | $ 1,200 | |||||
Equity interest percentage | 14.21% | |||||
Turner Imaging Systems | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Shares purchased (in shares) | shares | 2,100,000 | |||||
Investment at cost | $ 2,000 | |||||
Preferred stock issued upon conversion (in shares) | shares | 80,000 | |||||
Turner Imaging Systems | Promissory note | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Short-term debt | $ 100 | |||||
WhiteRabbit.ai Inc. | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Investment at cost | $ 1,000 | |||||
Shares acquired (in shares) | shares | 2,315,350 | |||||
Equity investment loan to company outstanding | $ 2,500 |
SUMMARY OF SIGNIFICANT ACCOU_19
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investment in Joint Ventures (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward] | |||
Beginning balance | $ 57,893 | $ 42,229 | |
Equity contributions in existing and purchase of interest in joint ventures | 43,993 | 9,712 | |
Equity in earnings in these joint ventures | 6,427 | 10,390 | $ 10,967 |
Distribution of earnings | (15,603) | (4,438) | |
Ending balance | $ 92,710 | $ 57,893 | $ 42,229 |
SUMMARY OF SIGNIFICANT ACCOU_20
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information8 (Details) $ in Millions | 12 Months Ended | |||
Nov. 01, 2022 USD ($) center | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Property, Plant and Equipment [Line Items] | ||||
Management service fees | $ 17.9 | $ 22.2 | $ 19.6 | |
Arizona Diagnostics Group | ||||
Property, Plant and Equipment [Line Items] | ||||
Additional contribution | $ 2.4 | $ 1.4 | ||
Number of assets sold | center | 8 | |||
Investment at cost | $ 12.7 | |||
Different between the sales price and carrying value | (0.5) | |||
Received a dividend from the partnership | 4.5 | |||
Book value of RadNet joint venture interests | $ 8.3 | |||
Equity interest percentage | 49% |
SUMMARY OF SIGNIFICANT ACCOU_21
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Key Financial Data on Joint Ventures (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Balance Sheet Data: | |||
Current assets | $ 579,276 | $ 367,184 | |
Current liabilities | (437,452) | (466,723) | |
Net revenue | 1,616,630 | 1,430,061 | $ 1,315,077 |
Net income | 30,337 | 33,608 | 44,319 |
Joint Venture Interest | |||
Balance Sheet Data: | |||
Total net assets | 147,334 | 106,458 | |
Equity Method Investment, Nonconsolidated Investee or Group of Investees | |||
Balance Sheet Data: | |||
Current assets | 39,819 | 39,304 | |
Noncurrent assets | 224,936 | 134,694 | |
Current liabilities | (46,587) | (29,588) | |
Noncurrent liabilities | (70,834) | (37,952) | |
Net revenue | 184,194 | 145,256 | 129,023 |
Net income | $ 12,968 | $ 21,169 | $ 21,893 |
SUMMARY OF SIGNIFICANT ACCOU_22
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Deferred Revenue Recognition (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 $ in Millions | Dec. 31, 2023 USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, amount | $ 1.3 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 12 months |
SUMMARY OF SIGNIFICANT ACCOU_23
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information9 (Details) $ in Thousands | 12 Months Ended | ||||||
Sep. 01, 2023 USD ($) location center | Jan. 01, 2019 | Apr. 01, 2017 | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Jan. 01, 2021 USD ($) | |
Property, Plant and Equipment [Line Items] | |||||||
Gain on disposal of equipment and other | $ (2,187) | $ (2,529) | $ (1,246) | ||||
Investment in joint ventures | $ 92,710 | $ 57,893 | $ 42,229 | $ 300 | |||
Los Angeles Imaging Group, LLC | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Economic interest | 65% | ||||||
Los Angeles Imaging Group, LLC | Cedars Sinai Medical Center | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Number of location | location | 3 | ||||||
Number of centers contributed | center | 3 | ||||||
Economic interest | 35% | ||||||
Limited partners' contributed capital | $ 5,900 | ||||||
Santa Monica Imaging Group, LLC | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Economic interest | 49% | 35% | 40% | ||||
Limited partners' contributed capital | $ 11,300 | ||||||
Gain on disposal of equipment and other | 16,800 | ||||||
Santa Monica Imaging Group, LLC | Cedars Sinai Medical Center | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Economic interest | 60% | ||||||
Limited liability company (LLC) or limited partnership (LP), managing member or general partner, ownership lnterest disposed | 5% | ||||||
Beverly Hills Imaging Center | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Limited partners' contributed capital | $ 27,200 |
BUSINESS COMBINATIONS AND REL_3
BUSINESS COMBINATIONS AND RELATED ACTIVITY - Assets and Liabilities Assumed (Details) $ in Thousands | Dec. 31, 2023 USD ($) | Aug. 01, 2023 USD ($) | Apr. 01, 2023 USD ($) | Feb. 01, 2023 USD ($) | Jan. 01, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 09, 2022 USD ($) | Dec. 01, 2022 USD ($) | Nov. 01, 2022 USD ($) loan | Oct. 01, 2022 USD ($) | Jan. 01, 2022 USD ($) | Dec. 31, 2021 USD ($) |
Business Acquisition [Line Items] | ||||||||||||
Goodwill | $ 679,463 | $ 677,665 | $ 513,820 | |||||||||
C.C.D.G.L.R. & S Services Inc. | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 3,500 | |||||||||||
Property and equipment | 435 | |||||||||||
Right of Use Assets | 1,689 | |||||||||||
Goodwill | 3,015 | |||||||||||
Intangible Assets | 50 | |||||||||||
Other | 0 | |||||||||||
Right of Use Liabilities | (1,689) | |||||||||||
Southern California Diagnostic Imaging, Inc. | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 1,815 | |||||||||||
Property and equipment | 466 | |||||||||||
Right of Use Assets | 1,184 | |||||||||||
Goodwill | 1,272 | |||||||||||
Intangible Assets | 50 | |||||||||||
Other | 27 | |||||||||||
Right of Use Liabilities | $ (1,184) | |||||||||||
Inglewood Imaging Center, LLC | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 2,600 | |||||||||||
Property and equipment | 877 | |||||||||||
Right of Use Assets | 1,188 | |||||||||||
Goodwill | 1,658 | |||||||||||
Intangible Assets | 50 | |||||||||||
Other | 15 | |||||||||||
Right of Use Liabilities | (1,188) | |||||||||||
Ramapo Radiology Associates, P.C. | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 2,000 | |||||||||||
Property and equipment | 1,663 | |||||||||||
Right of Use Assets | 3,775 | |||||||||||
Goodwill | 229 | |||||||||||
Intangible Assets | 100 | |||||||||||
Other | 8 | |||||||||||
Right of Use Liabilities | $ (3,775) | |||||||||||
Madison Radiology Medical Group, Inc. | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 250 | |||||||||||
Property and equipment | 100 | |||||||||||
Right of Use Assets | 0 | |||||||||||
Goodwill | 150 | |||||||||||
Intangible Assets | 0 | |||||||||||
Other | 0 | |||||||||||
Right of Use Liabilities | $ 0 | |||||||||||
Delaware Diagnostic Imaging, P.A. | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 600 | |||||||||||
Property and equipment | 401 | |||||||||||
Right of Use Assets | 337 | |||||||||||
Goodwill | 149 | |||||||||||
Intangible Assets | 50 | |||||||||||
Other | 0 | |||||||||||
Right of Use Liabilities | $ (337) | |||||||||||
I F R C L L C Subsidiary One | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 8,200 | |||||||||||
Property and equipment | 2,910 | |||||||||||
Right of Use Assets | 1,703 | |||||||||||
Goodwill | 5,271 | |||||||||||
Intangible Assets | 0 | |||||||||||
Other | 19 | |||||||||||
Right of Use Liabilities | (1,703) | |||||||||||
I F R C L L C Subsidiary Two | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 4,800 | |||||||||||
Property and equipment | 2,103 | |||||||||||
Right of Use Assets | 857 | |||||||||||
Goodwill | 2,697 | |||||||||||
Intangible Assets | 0 | |||||||||||
Other | 0 | |||||||||||
Right of Use Liabilities | $ (857) | |||||||||||
Montclair Radiological Associates, P.A. | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 94,877 | |||||||||||
Property and equipment | 16,414 | |||||||||||
Right of Use Assets | 4,665 | |||||||||||
Goodwill | 79,690 | |||||||||||
Intangible Assets | 400 | |||||||||||
Other | (2,168) | |||||||||||
Right of Use Liabilities | (4,124) | |||||||||||
Contingent consideration to guarantee share value issued | $ 1,200 | |||||||||||
Heart & Lung Imaging Limited | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 32,000 | |||||||||||
Property and equipment | 0 | |||||||||||
Right of Use Assets | 0 | |||||||||||
Goodwill | 16,200 | |||||||||||
Intangible Assets | 15,800 | |||||||||||
Other | 0 | |||||||||||
Right of Use Liabilities | 0 | |||||||||||
Contingent consideration to guarantee share value issued | 6,879 | 11,656 | $ 10,800 | $ 0 | ||||||||
Chelsea Dignostic Radiology, P.C. | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 2,800 | |||||||||||
Property and equipment | 568 | |||||||||||
Right of Use Assets | 0 | |||||||||||
Goodwill | 2,132 | |||||||||||
Intangible Assets | 100 | |||||||||||
Other | 0 | |||||||||||
Right of Use Liabilities | $ 0 | |||||||||||
North Jersey Imaging Center, LLC | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 104 | |||||||||||
Property and equipment | 20 | |||||||||||
Right of Use Assets | 0 | |||||||||||
Goodwill | 55 | |||||||||||
Intangible Assets | 25 | |||||||||||
Other | 4 | |||||||||||
Right of Use Liabilities | $ 0 | |||||||||||
I F R C L L C | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Number of subsidiaries acquired | loan | 3 | |||||||||||
I F R C L L C | Joint Venture With Calvert Medical Imaging Centers LLC | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Number of subsidiaries acquired | loan | 1 | |||||||||||
Business Acquisitions | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 10,765 | 142,781 | ||||||||||
Property and equipment | 3,942 | 22,015 | ||||||||||
Right of Use Assets | 8,173 | 7,225 | ||||||||||
Goodwill | 6,473 | 106,045 | ||||||||||
Intangible Assets | 300 | 16,325 | ||||||||||
Other | 50 | (2,145) | ||||||||||
Right of Use Liabilities | $ (8,173) | $ (6,684) |
BUSINESS COMBINATIONS AND REL_4
BUSINESS COMBINATIONS AND RELATED ACTIVITY - Additional Information1 (Details) - USD ($) $ / shares in Units, $ in Thousands | Nov. 01, 2022 | Dec. 31, 2023 | Sep. 20, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Business Acquisition [Line Items] | |||||
Goodwill | $ 679,463 | $ 677,665 | $ 513,820 | ||
Heart & Lung Imaging Limited | |||||
Business Acquisition [Line Items] | |||||
Business acquisition, percentage of voting interests acquired | 75% | ||||
Consideration transferred | $ 31,900 | ||||
Common stock issued as consideration | $ 6,800 | ||||
Shares issued (in shares) | 359,002 | ||||
Price per share (dollars per share) | $ 19.06 | ||||
Consideration transferred | $ 6,300 | ||||
Contingent consideration to guarantee share value issued | $ 10,800 | 6,879 | 11,656 | $ 0 | |
Business combination, contingent consideration, liability, period | 24 months | ||||
Business combination, noncontrolling interest | $ 8,000 | ||||
Current assets acquired | 600 | ||||
Intangible assets | 15,800 | ||||
Liabilities | 600 | ||||
Goodwill | $ 16,200 | ||||
Heart & Lung Imaging Limited | Measurement Input, Discount Rate | Valuation, Income Approach | |||||
Business Acquisition [Line Items] | |||||
Contingent consideration liability, measurement input | 0.190 | ||||
Heart & Lung Imaging Limited | Contingent Milestone Consideration | |||||
Business Acquisition [Line Items] | |||||
Contingent consideration to guarantee share value issued | $ 10,200 | $ 6,200 | $ 1,600 | $ 11,100 | |
Heart & Lung Imaging Limited | Cash Holdback | |||||
Business Acquisition [Line Items] | |||||
Contingent consideration to guarantee share value issued | $ 600 |
BUSINESS COMBINATIONS AND REL_5
BUSINESS COMBINATIONS AND RELATED ACTIVITY - Additional Information2 (Details) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Jan. 20, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Business Acquisition [Line Items] | ||||
Goodwill | $ 679,463 | $ 677,665 | $ 513,820 | |
Minimum | Measurement Input, Discount Rate | Valuation, Income Approach | ||||
Business Acquisition [Line Items] | ||||
Contingent consideration liability, measurement input | 0.15 | |||
Maximum | Measurement Input, Discount Rate | Valuation, Income Approach | ||||
Business Acquisition [Line Items] | ||||
Contingent consideration liability, measurement input | 0.17 | |||
Software developed for internal use | ||||
Business Acquisition [Line Items] | ||||
Amortization period | 7 years | |||
Customer Relationships | ||||
Business Acquisition [Line Items] | ||||
Amortization period | 3 years | |||
Trade Names | ||||
Business Acquisition [Line Items] | ||||
Amortization period | 7 years | |||
Aidence | ||||
Business Acquisition [Line Items] | ||||
Intangible assets acquired | $ 27,700 | |||
Liabilities | 3,200 | |||
Deferred tax liabilities acquired | 3,500 | |||
Goodwill | 22,900 | |||
Impairment of intangible assets | $ 3,900 | |||
Aidence | Software developed for internal use | ||||
Business Acquisition [Line Items] | ||||
Intangible assets acquired | 21,100 | |||
Amortization period | 7 years | |||
Aidence | In Process Research and Development | ||||
Business Acquisition [Line Items] | ||||
Intangible assets acquired | $ 5,500 | |||
Aidence | Customer Relationships | ||||
Business Acquisition [Line Items] | ||||
Amortization period | 5 years 4 months 24 days | |||
Aidence | Trade Names | ||||
Business Acquisition [Line Items] | ||||
Amortization period | 7 years |
BUSINESS COMBINATIONS AND REL_6
BUSINESS COMBINATIONS AND RELATED ACTIVITY - Additional Information3 (Details) $ / shares in Units, $ in Thousands | 12 Months Ended | |||||
Nov. 01, 2022 USD ($) $ / shares shares | Jan. 20, 2022 USD ($) $ / shares shares | Dec. 31, 2023 USD ($) | Sep. 20, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Business Acquisition [Line Items] | ||||||
Goodwill | $ 679,463 | $ 677,665 | $ 513,820 | |||
Minimum | Measurement Input, Discount Rate | Valuation, Income Approach | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration liability, measurement input | 0.15 | |||||
Maximum | Measurement Input, Discount Rate | Valuation, Income Approach | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration liability, measurement input | 0.17 | |||||
Software developed for internal use | ||||||
Business Acquisition [Line Items] | ||||||
Amortization period | 7 years | |||||
Customer Relationships | ||||||
Business Acquisition [Line Items] | ||||||
Amortization period | 3 years | |||||
Trade Names | ||||||
Business Acquisition [Line Items] | ||||||
Amortization period | 7 years | |||||
Quantib | ||||||
Business Acquisition [Line Items] | ||||||
Consideration transferred | $ 42,300 | |||||
Common stock issued as consideration | $ 25,900 | |||||
Shares issued (in shares) | shares | 965,058 | |||||
Consideration transferred | $ 11,800 | |||||
Contingent consideration to guarantee share value issued | $ 0 | 3,709 | 0 | |||
Business combination, contingent consideration, liability, period | 18 months | |||||
Current assets acquired | $ 2,400 | |||||
Liabilities | 700 | |||||
Goodwill | 26,400 | |||||
Property and equipment | 100 | |||||
Intangible assets acquired | 21,300 | |||||
Long-term liabilities assumed | 6,700 | |||||
Quantib | Minimum | Measurement Input, Discount Rate | Valuation, Income Approach | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration liability, measurement input | 0.50 | |||||
Quantib | Maximum | Measurement Input, Discount Rate | Valuation, Income Approach | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration liability, measurement input | 0.55 | |||||
Quantib | Software developed for internal use | ||||||
Business Acquisition [Line Items] | ||||||
Intangible assets acquired | 19,600 | |||||
Quantib | In Process Research and Development | ||||||
Business Acquisition [Line Items] | ||||||
Intangible assets acquired | 700 | |||||
Quantib | Business Acsuition Contingent Consideration | ||||||
Business Acquisition [Line Items] | ||||||
Common stock issued as consideration | $ 3,000 | |||||
Shares issued (in shares) | shares | 113,303 | |||||
Quantib | Cash Holdback | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration to guarantee share value issued | $ 1,600 | $ 1,600 | ||||
Quantib | Other Sellers | ||||||
Business Acquisition [Line Items] | ||||||
Price per share (dollars per share) | $ / shares | $ 26.80 | |||||
Heart & Lung Imaging Limited | ||||||
Business Acquisition [Line Items] | ||||||
Business acquisition, percentage of voting interests acquired | 75% | |||||
Consideration transferred | $ 31,900 | |||||
Common stock issued as consideration | $ 6,800 | |||||
Shares issued (in shares) | shares | 359,002 | |||||
Price per share (dollars per share) | $ / shares | $ 19.06 | |||||
Consideration transferred | $ 6,300 | |||||
Contingent consideration to guarantee share value issued | $ 10,800 | 6,879 | 11,656 | 0 | ||
Business combination, contingent consideration, liability, period | 24 months | |||||
Business combination, noncontrolling interest | $ 8,000 | |||||
Current assets acquired | 600 | |||||
Intangible assets | 15,800 | |||||
Liabilities | 600 | |||||
Goodwill | 16,200 | |||||
Property and equipment | $ 0 | |||||
Heart & Lung Imaging Limited | Measurement Input, Discount Rate | Valuation, Income Approach | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration liability, measurement input | 0.190 | |||||
Heart & Lung Imaging Limited | Cash Holdback | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration to guarantee share value issued | $ 600 | |||||
Heart & Lung Imaging Limited | Contingent Milestone Consideration | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration to guarantee share value issued | $ 10,200 | 6,200 | $ 1,600 | 11,100 | ||
Aidence | ||||||
Business Acquisition [Line Items] | ||||||
Consideration transferred | $ 45,200 | |||||
Shares issued (in shares) | shares | 359,002 | 1,141,234 | ||||
Consideration transferred | $ 1,800 | |||||
Contingent consideration to guarantee share value issued | 11,900 | $ 0 | 11,158 | $ 0 | ||
Current assets acquired | 1,000 | |||||
Liabilities | 3,200 | |||||
Goodwill | 22,900 | |||||
Settlement of loan | 1,500 | |||||
Property and equipment | 200 | |||||
Intangible assets acquired | 27,700 | |||||
Deferred tax liabilities acquired | 3,500 | |||||
Aidence | Software developed for internal use | ||||||
Business Acquisition [Line Items] | ||||||
Intangible assets acquired | 21,100 | |||||
Amortization period | 7 years | |||||
Aidence | In Process Research and Development | ||||||
Business Acquisition [Line Items] | ||||||
Intangible assets acquired | 5,500 | |||||
Aidence | Customer Relationships | ||||||
Business Acquisition [Line Items] | ||||||
Amortization period | 5 years 4 months 24 days | |||||
Aidence | Trade Names | ||||||
Business Acquisition [Line Items] | ||||||
Amortization period | 7 years | |||||
Aidence | Cash Holdback | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration to guarantee share value issued | 4,500 | $ 4,000 | ||||
Aidence | Contingent Milestone Consideration | ||||||
Business Acquisition [Line Items] | ||||||
Contingent consideration to guarantee share value issued | 7,400 | $ 7,200 | ||||
Aidence | Other Sellers | ||||||
Business Acquisition [Line Items] | ||||||
Common stock issued as consideration | $ 30,000 | |||||
Shares issued (in shares) | shares | 1,117,872 | |||||
Price per share (dollars per share) | $ / shares | $ 26.80 | |||||
Aidence | Certain Seller | ||||||
Business Acquisition [Line Items] | ||||||
Common stock issued as consideration | $ 600 | |||||
Shares issued (in shares) | shares | 23,362 |
BUSINESS COMBINATIONS AND REL_7
BUSINESS COMBINATIONS AND RELATED ACTIVITY - Additional Information4 (Details) $ in Thousands | 12 Months Ended | ||||||
Sep. 01, 2023 USD ($) location center | Apr. 01, 2022 USD ($) center location | Sep. 01, 2021 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Aug. 31, 2021 | |
Business Acquisition [Line Items] | |||||||
Property and equipment, net | $ 604,401 | $ 565,961 | |||||
Goodwill | 679,463 | 677,665 | $ 513,820 | ||||
Gain (loss) on disposition of property plant equipment | (2,187) | (2,529) | (1,246) | ||||
Sale to noncontrolling interests, net of taxes | 2,236 | 6,623 | 11,610 | ||||
Purchase of intangible assets | 0 | 0 | 5,130 | ||||
Tarzana Medical Center, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Purchase of intangible assets | $ 5,200 | ||||||
Additional Paid-in Capital | |||||||
Business Acquisition [Line Items] | |||||||
Sale to noncontrolling interests, net of taxes | $ 4,200 | $ 2,236 | $ 6,623 | $ 4,206 | |||
Frederick County Radiology, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Economic interest | 65% | ||||||
Frederick County Radiology, LLC | Additional Paid-in Capital | |||||||
Business Acquisition [Line Items] | |||||||
Gain (loss) on disposition of property plant equipment | $ 6,600 | ||||||
Los Angeles Imaging Group, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Economic interest | 65% | ||||||
West Valley Imaging Group, LLC | Subsidiaries | |||||||
Business Acquisition [Line Items] | |||||||
Noncontrolling interest, percent of ownership sold | 24.90% | ||||||
Proceeds from sale of interest in minority shareholders | $ 13,100 | ||||||
Noncontrolling interest, ownership percentage by parent | 50.10% | 75% | |||||
Frederick County Radiology, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Number of centers contributed | center | 4 | ||||||
Frederick County Radiology, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Number of location | location | 6 | ||||||
Frederick Health Hospital, Inc. | Frederick County Radiology, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Property and equipment, net | $ 8,400 | ||||||
Goodwill | $ 11,000 | ||||||
Minority partner ownership percent | 35% | ||||||
Frederick Health Hospital, Inc. | Frederick County Radiology, LLC | Fixed Assets | |||||||
Business Acquisition [Line Items] | |||||||
Property and equipment, net | $ 5,400 | ||||||
Frederick Health Hospital, Inc. | Frederick County Radiology, LLC | Medical equipment | |||||||
Business Acquisition [Line Items] | |||||||
Property and equipment, net | 3,000 | ||||||
Frederick Health Hospital, Inc. | Frederick County Radiology, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Book value of RadNet joint venture interests | $ 11,100 | ||||||
Cedars Sinai Medical Center | Los Angeles Imaging Group, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Number of location | location | 3 | ||||||
Number of centers contributed | center | 3 | ||||||
Economic interest | 35% | ||||||
Limited partners' contributed capital | $ 5,900 |
SEGMENT REPORTING (Details)
SEGMENT REPORTING (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2024 loan | Dec. 31, 2023 USD ($) loan | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Segment Reporting Information [Line Items] | ||||
Revenue: | $ 1,616,630 | $ 1,430,061 | $ 1,315,077 | |
Cost of Operations | 1,395,239 | 1,264,346 | 1,123,274 | |
Gain on contribution of imaging centers into joint venture | (16,808) | 0 | 0 | |
Lease abandonment charges | 5,146 | 0 | 19,675 | |
Depreciation and Amortization | 128,391 | 115,877 | 96,694 | |
Loss on Disposal of Equipment | 2,187 | 2,529 | 1,246 | |
Severance | 3,778 | 946 | 744 | |
Income from Operations | $ 98,697 | 46,363 | 73,444 | |
Number of reportable segments | loan | 2 | |||
Forecast | ||||
Segment Reporting Information [Line Items] | ||||
Number of reportable segments | loan | 2 | |||
Third Party | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | $ 1,616,630 | 1,430,061 | ||
Intersegment | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 0 | 0 | ||
Imaging Centers | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 1,604,161 | 1,425,665 | 1,313,662 | |
Cost of Operations | 1,371,036 | 1,240,593 | 1,117,941 | |
Gain on contribution of imaging centers into joint venture | (16,808) | 0 | 0 | |
Lease abandonment charges | 5,146 | 0 | 19,675 | |
Depreciation and Amortization | 120,776 | 109,524 | 96,174 | |
Loss on Disposal of Equipment | 2,191 | 2,506 | 1,246 | |
Severance | 1,973 | 926 | 744 | |
Income from Operations | 119,847 | 72,116 | 77,882 | |
AI | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 12,469 | 4,396 | 1,415 | |
Cost of Operations | 24,203 | 23,753 | 5,333 | |
Gain on contribution of imaging centers into joint venture | 0 | 0 | 0 | |
Lease abandonment charges | 0 | 0 | 0 | |
Depreciation and Amortization | 7,615 | 6,353 | 520 | |
Loss on Disposal of Equipment | (4) | 23 | 0 | |
Severance | 1,805 | 20 | 0 | |
Income from Operations | (21,150) | (25,753) | $ (4,438) | |
Operating Segments | Imaging Centers | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 1,610,707 | 1,425,665 | ||
Operating Segments | Imaging Centers | Third Party | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 1,610,707 | 1,425,665 | ||
Operating Segments | Imaging Centers | Intersegment | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 0 | 0 | ||
Operating Segments | AI | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 12,469 | 4,396 | ||
Operating Segments | AI | Third Party | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 5,923 | 4,396 | ||
Operating Segments | AI | Intersegment | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 6,546 | 0 | ||
Intersegment Elimination | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | (6,546) | 0 | ||
Intersegment Elimination | Third Party | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | 0 | 0 | ||
Intersegment Elimination | Intersegment | ||||
Segment Reporting Information [Line Items] | ||||
Revenue: | $ (6,546) | $ 0 |
GOODWILL AND OTHER INTANGIBLE_3
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Goodwill [Roll Forward] | ||
Goodwill, beginning balance | $ 677,665 | $ 513,820 |
Additions | 6,473 | 169,248 |
Disposals | (9,235) | (4,200) |
Measurement period and other adjustments | 1,603 | 41 |
Currency translation | 2,957 | (1,244) |
Goodwill, ending balance | 679,463 | 677,665 |
Imaging Centers | ||
Goodwill [Roll Forward] | ||
Goodwill, beginning balance | 606,483 | 489,210 |
Additions | 6,473 | 120,551 |
Disposals | (9,235) | (4,200) |
Measurement period and other adjustments | 1,603 | (106) |
Currency translation | 1,233 | 1,028 |
Goodwill, ending balance | 606,557 | 606,483 |
AI | ||
Goodwill [Roll Forward] | ||
Goodwill, beginning balance | 71,182 | 24,610 |
Additions | 0 | 48,697 |
Disposals | 0 | 0 |
Measurement period and other adjustments | 0 | 147 |
Currency translation | 1,724 | (2,272) |
Goodwill, ending balance | $ 72,906 | $ 71,182 |
GOODWILL AND OTHER INTANGIBLE_4
GOODWILL AND OTHER INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | |||
Goodwill deductible for tax purpose | $ 142.7 | ||
Amortization expense | $ 12.2 | $ 10.1 | $ 4.4 |
Management Service Contracts | |||
Finite-Lived Intangible Assets [Line Items] | |||
Amortization period | 25 years |
GOODWILL AND OTHER INTANGIBLE_5
GOODWILL AND OTHER INTANGIBLE ASSETS - Annual Amortization Schedule (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
2024 | $ 12,645 | |
2025 | 12,283 | |
2026 | 11,833 | |
2027 | 10,818 | |
2028 | 10,505 | |
Thereafter | 32,531 | |
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite lived intangible assets | 9,000 | $ 24,100 |
Other intangible assets | 90,615 | $ 106,228 |
Trade Names | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite lived intangible assets | 7,100 | |
Software costs | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite lived intangible assets | 1,882 | |
Management Service Contracts | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | 2,287 | |
2025 | 2,287 | |
2026 | 2,287 | |
2027 | 2,287 | |
2028 | 2,287 | |
Thereafter | 6,671 | |
Total | $ 18,106 | |
Weighted average amortization period remaining in years | 7 years 10 months 24 days | |
Covenant not to compete and other contracts | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | $ 946 | |
2025 | 714 | |
2026 | 427 | |
2027 | 132 | |
2028 | 45 | |
Thereafter | 6 | |
Total | $ 2,270 | |
Weighted average amortization period remaining in years | 3 years 4 months 24 days | |
Customer Relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | $ 1,234 | |
2025 | 1,104 | |
2026 | 981 | |
2027 | 797 | |
2028 | 764 | |
Thereafter | 10,564 | |
Total | $ 15,444 | |
Weighted average amortization period remaining in years | 17 years 8 months 12 days | |
Patent and Trademarks | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | $ 316 | |
2025 | 316 | |
2026 | 316 | |
2027 | 315 | |
2028 | 300 | |
Thereafter | 164 | |
Total | $ 1,727 | |
Weighted average amortization period remaining in years | 5 years 9 months 18 days | |
Developed Technology & Software | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | $ 7,785 | |
2025 | 7,785 | |
2026 | 7,745 | |
2027 | 7,210 | |
2028 | 7,046 | |
Thereafter | 6,117 | |
Total | $ 43,688 | |
Weighted average amortization period remaining in years | 5 years 8 months 12 days | |
Trade Names | ||
Finite-Lived Intangible Assets [Line Items] | ||
2024 | $ 77 | |
2025 | 77 | |
2026 | 77 | |
2027 | 77 | |
2028 | 63 | |
Thereafter | 27 | |
Total | $ 398 | |
Weighted average amortization period remaining in years | 5 years 3 months 18 days |
PROPERTY AND EQUIPMENT - Schedu
PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Equipment at cost | $ 13,971 | $ 13,971 |
Total property and equipment cost | 1,441,300 | 1,320,700 |
Accumulated depreciation | (836,899) | (754,739) |
Total property and equipment | 604,401 | 565,961 |
Land | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 250 | 250 |
Medical equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 714,400 | 649,034 |
Computer and office equipment, furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 127,540 | 119,467 |
Software costs | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 47,286 | 36,015 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 537,853 | $ 501,963 |
PROPERTY AND EQUIPMENT - Additi
PROPERTY AND EQUIPMENT - Additional Information (Details ) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | |||
Depreciation and amortization expense | $ 116,200 | $ 105,600 | $ 92,300 |
Construction in Progress | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 42,700 | 73,400 | |
Medical Equipment | |||
Property, Plant and Equipment [Line Items] | |||
Construction in progress, gross | 12,200 | 26,600 | |
Computer and Office Equipment | |||
Property, Plant and Equipment [Line Items] | |||
Construction in progress, gross | 1,900 | 5,300 | |
Software costs | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 47,286 | 36,015 | |
Construction in progress, gross | 6,000 | 400 | |
Leasehold improvements | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 537,853 | 501,963 | |
Construction in progress, gross | $ 22,600 | $ 41,100 |
CREDIT FACILITIES AND NOTES P_3
CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Debt (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | ||
Debt | $ 830,042 | $ 851,744 |
Total debt obligations | 830,042 | 851,744 |
Less current portion | (17,974) | (12,400) |
Long-term portion of debt obligations | 812,068 | 839,344 |
Term Loan | Term Loans | ||
Debt Instrument [Line Items] | ||
Debt | 678,687 | 714,125 |
Discount on debt | (9,041) | (11,127) |
Total debt obligations | 678,687 | 714,125 |
Term Loan | Restated Agreement | ||
Debt Instrument [Line Items] | ||
Debt | 144,375 | 150,000 |
Discount on debt | (990) | (1,254) |
Total debt obligations | $ 144,375 | 150,000 |
Secured Debt | 6.0% Notes due 2028 | ||
Debt Instrument [Line Items] | ||
Debt instrument, interest rate | 6% | |
Equipment notes payable at 6.0%, due 2028, collateralized by medical equipment | $ 17,011 | $ 0 |
CREDIT FACILITIES AND NOTES P_4
CREDIT FACILITIES AND NOTES PAYABLE - Annual Note Payable Maturities (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
Maturities of Notes Payables [Abstract] | |
2024 | $ 20,324 |
2025 | 22,431 |
2026 | 22,676 |
2027 | 124,188 |
2028 | 650,454 |
Total notes payable obligations | $ 840,073 |
CREDIT FACILITIES AND NOTES P_5
CREDIT FACILITIES AND NOTES PAYABLE - Additional Information (Details) - USD ($) | Dec. 31, 2023 | Mar. 27, 2023 | Apr. 23, 2021 |
Barclays | One Month Secured Overnight Financing Rate (SOFR) | |||
Line of Credit Facility [Line Items] | |||
Debt instrument, interest rate | 0.11448% | ||
Barclays | Three Months Secured Overnight Financing Rate (SOFR) | |||
Line of Credit Facility [Line Items] | |||
Debt instrument, interest rate | 0.26161% | ||
Barclays | Six Months Secured Overnight Financing Rate (SOFR) | |||
Line of Credit Facility [Line Items] | |||
Debt instrument, interest rate | 0.42826% | ||
Revolving Credit Facility | |||
Line of Credit Facility [Line Items] | |||
Letters of credit outstanding, amount | $ 7,600,000 | ||
Revolving Credit Facility | Barclays | |||
Line of Credit Facility [Line Items] | |||
Credit facility, borrowings available | 187,400,000 | ||
Revolving Credit Facility | SunTrust | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Credit facilities available | 50,000,000 | ||
Revolving Credit Facility | First Lien Credit Agreement | Barclays | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Total credit facilities outstanding | 0 | ||
Revolving Credit Facility | First Lien Credit Agreement | SunTrust | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Total credit facilities outstanding | $ 0 | ||
Revolving Credit Facility | First Lien Credit Agreement Eighth Amendment | Barclays | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Credit facilities available | $ 195,000,000 |
CREDIT FACILITIES AND NOTES P_6
CREDIT FACILITIES AND NOTES PAYABLE- Second Amended and Restated First Lien Credit and Guaranty Agreement (Details) - USD ($) | 12 Months Ended | |||||
Oct. 07, 2022 | Apr. 23, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Aug. 31, 2018 | |
Debt Instrument [Line Items] | ||||||
Deferred financing costs, net of accumulated amortization | $ 1,600,000 | $ 2,300,000 | ||||
Loss on extinguishment of debt | 0 | $ 0 | $ 1,496,000 | |||
Revolving Credit Facility | Barclays | ||||||
Debt Instrument [Line Items] | ||||||
Deferred financing costs, net of accumulated amortization | 1,100,000 | |||||
Medium-term Notes | Barclays | ||||||
Debt Instrument [Line Items] | ||||||
Total credit facilities outstanding | $ 725,000,000 | |||||
Medium-term Notes | Truist | ||||||
Debt Instrument [Line Items] | ||||||
Total credit facilities outstanding | $ 150,000,000 | |||||
Line of Credit | Revolving Credit Facility | Truist | ||||||
Debt Instrument [Line Items] | ||||||
Credit facilities available | $ 30,000,000 | |||||
Line of Credit | Revolving Credit Facility | First Lien Credit Agreement Eighth Amendment | Barclays | ||||||
Debt Instrument [Line Items] | ||||||
Credit facilities available | 195,000,000 | |||||
Line of Credit | Revolving Credit Facility | First Lien Credit Agreement Eighth Amendment | Truist | ||||||
Debt Instrument [Line Items] | ||||||
Credit facilities available | 50,000,000 | |||||
Deferred financing costs, net of accumulated amortization | $ 500,000 | |||||
Amendment No. 7 First Lien Credit Agreement | Barclays | ||||||
Debt Instrument [Line Items] | ||||||
Issuance costs | 14,900,000 | |||||
Debt instrument, unamortized discount, current | 8,800,000 | |||||
Deferred financing costs, net of accumulated amortization | 4,500,000 | |||||
Loss on extinguishment of debt | 1,500,000 | |||||
Amortization of deferred charges | $ 100,000 | |||||
Amendment No. 7 First Lien Credit Agreement | Truist | ||||||
Debt Instrument [Line Items] | ||||||
Issuance costs | 2,700,000 | |||||
Debt instrument, unamortized discount, current | 2,000,000 | |||||
Loss on extinguishment of debt | $ 700,000 |
CREDIT FACILITIES AND NOTES P_7
CREDIT FACILITIES AND NOTES PAYABLE - Margin Spread Based on Leverage Ratio, Debt Instrument) (Details) - Restated Agreement | 12 Months Ended |
Dec. 31, 2023 | |
Pricing Level I | |
Debt Instrument [Line Items] | |
Leverage ratio, greater than | 3 |
Pricing Level II | |
Debt Instrument [Line Items] | |
Leverage ratio, greater than | 2.50 |
Leverage ratio, less than | 3 |
Pricing Level III | |
Debt Instrument [Line Items] | |
Leverage ratio, greater than | 2 |
Leverage ratio, less than | 2.50 |
Pricing Level IV | |
Debt Instrument [Line Items] | |
Leverage ratio, greater than | 1.50 |
Leverage ratio, less than | 2 |
Pricing Level V | |
Debt Instrument [Line Items] | |
Leverage ratio, less than | 1.50 |
Revolving Credit Facility | Pricing Level I | |
Debt Instrument [Line Items] | |
Commitment fee percentage | 2.50% |
Unused capacity, commitment fee percentage | 0.45% |
Revolving Credit Facility | Pricing Level I | Eurodollar | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 2.50% |
Revolving Credit Facility | Pricing Level I | Alternative Base Rate Spread | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 1.50% |
Revolving Credit Facility | Pricing Level II | |
Debt Instrument [Line Items] | |
Commitment fee percentage | 2.25% |
Unused capacity, commitment fee percentage | 0.40% |
Revolving Credit Facility | Pricing Level II | Eurodollar | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 2.25% |
Revolving Credit Facility | Pricing Level II | Alternative Base Rate Spread | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 1.25% |
Revolving Credit Facility | Pricing Level III | |
Debt Instrument [Line Items] | |
Commitment fee percentage | 2% |
Unused capacity, commitment fee percentage | 0.35% |
Revolving Credit Facility | Pricing Level III | Eurodollar | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 2% |
Revolving Credit Facility | Pricing Level III | Alternative Base Rate Spread | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 1% |
Revolving Credit Facility | Pricing Level IV | |
Debt Instrument [Line Items] | |
Commitment fee percentage | 1.75% |
Unused capacity, commitment fee percentage | 0.30% |
Revolving Credit Facility | Pricing Level IV | Eurodollar | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 1.75% |
Revolving Credit Facility | Pricing Level IV | Alternative Base Rate Spread | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 0.75% |
Revolving Credit Facility | Pricing Level V | |
Debt Instrument [Line Items] | |
Commitment fee percentage | 1.50% |
Unused capacity, commitment fee percentage | 0.30% |
Revolving Credit Facility | Pricing Level V | Eurodollar | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 1.50% |
Revolving Credit Facility | Pricing Level V | Alternative Base Rate Spread | |
Debt Instrument [Line Items] | |
Basis spread on variable rate | 0.50% |
CREDIT FACILITIES AND NOTES P_8
CREDIT FACILITIES AND NOTES PAYABLE - Senior Credit Facilities (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2023 | Dec. 31, 2023 | Mar. 27, 2023 | |
One Month Secured Overnight Financing Rate (SOFR) | Barclays | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, interest rate | 0.11448% | |||
Medium-term Notes | Truist | ||||
Debt Instrument [Line Items] | ||||
Debt periodic payment | $ 1.9 | |||
Debt periodic payment, percent of total amount | 1% | |||
Debt periodic payment, amortization increase | $ 0.9 | $ 0.9 | ||
Medium-term Notes | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Truist | ||||
Debt Instrument [Line Items] | ||||
Basis spread on variable rate | 5.33% | |||
Term Loans | Term Loan | Barclays | ||||
Debt Instrument [Line Items] | ||||
Periodic payment, principal | $ 1.8 | |||
Revolving Credit Facility | Barclays | ||||
Debt Instrument [Line Items] | ||||
Effective interest rate | 10.30% | |||
Revolving Credit Facility | Amendment No. 6 First Lien Credit Agreement | Line of Credit | Eurodollar | ||||
Debt Instrument [Line Items] | ||||
Effective interest rate | 4.63% | 4.63% | ||
Revolving Credit Facility | Amendment No. 6 First Lien Credit Agreement | Line of Credit | Eurodollar | ≤ 3.00x | ||||
Debt Instrument [Line Items] | ||||
Basis spread on variable rate | 3% | |||
Revolving Credit Facility | Amendment No. 6 First Lien Credit Agreement | Line of Credit | Alternative Base Rate Spread | ||||
Debt Instrument [Line Items] | ||||
Effective interest rate | 8% | 8% | ||
Revolving Credit Facility | Amendment No. 6 First Lien Credit Agreement | Line of Credit | Alternative Base Rate Spread | ≤ 3.00x | ||||
Debt Instrument [Line Items] | ||||
Basis spread on variable rate | 2% | |||
Revolving Credit Facility | Term Loans | Alternative Base Rate Spread | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, interest rate | 10.50% | |||
Revolving Credit Facility | Term Loans | Secured Overnight Financing Rate (SOFR) | ||||
Debt Instrument [Line Items] | ||||
Effective interest rate | 8.38% | |||
Debt instrument, interest rate | 0.26161% |
CREDIT FACILITIES AND NOTES P_9
CREDIT FACILITIES AND NOTES PAYABLE - Revolving Credit Facilities (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Aug. 31, 2018 | |
Line of Credit Facility [Line Items] | |||
Deferred financing costs, net of accumulated amortization | $ 1,600,000 | $ 2,300,000 | |
Revolving Credit Facility | Barclays | |||
Line of Credit Facility [Line Items] | |||
Deferred financing costs, net of accumulated amortization | $ 1,100,000 | ||
Effective interest rate | 10.30% | ||
Revolving Credit Facility | Truist | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Credit facilities available | $ 30,000,000 | ||
Revolving Credit Facility | First Lien Credit Agreement | Line of Credit | ≤ 3.00x | Secured Overnight Financing Rate (SOFR) | |||
Line of Credit Facility [Line Items] | |||
Basis spread on variable rate | 2.75% | ||
Revolving Credit Facility | First Lien Credit Agreement | Line of Credit | > 3.50x | Secured Overnight Financing Rate (SOFR) | |||
Line of Credit Facility [Line Items] | |||
Basis spread on variable rate | 3.25% | ||
Revolving Credit Facility | First Lien Credit Agreement | Line of Credit | > 3.00x but ≤ 3.50x | Secured Overnight Financing Rate (SOFR) | |||
Line of Credit Facility [Line Items] | |||
Basis spread on variable rate | 3% | ||
Letter of Credit | Barclays | Letter of Credit | |||
Line of Credit Facility [Line Items] | |||
Commitment fee percentage | 0.125% | ||
Unused capacity, commitment fee percentage | 0.50% | ||
Letter of Credit | Amendment No. 6 First Lien Credit Agreement | Line of Credit | ≤ 3.00x | Secured Overnight Financing Rate (SOFR) | |||
Line of Credit Facility [Line Items] | |||
Basis spread on variable rate | 3% |
CREDIT FACILITIES AND NOTES _10
CREDIT FACILITIES AND NOTES PAYABLE - Margin Spread Based on Leverage Ratio (Details) - Line of Credit - Revolving Credit Facility - First Lien Credit Agreement | 12 Months Ended |
Dec. 31, 2023 | |
> 3.50x | |
Line of Credit Facility [Line Items] | |
Debt instrument, leverage ratio | 3.50 |
> 3.00x but ≤ 3.50x | Minimum | |
Line of Credit Facility [Line Items] | |
Debt instrument, leverage ratio | 3 |
> 3.00x but ≤ 3.50x | Maximum | |
Line of Credit Facility [Line Items] | |
Debt instrument, leverage ratio | 3.50 |
≤ 3.00x | |
Line of Credit Facility [Line Items] | |
Debt instrument, leverage ratio | 3 |
Alternative Base Rate Spread | > 3.50x | |
Line of Credit Facility [Line Items] | |
Basis spread on variable rate | 2.25% |
Alternative Base Rate Spread | > 3.00x but ≤ 3.50x | |
Line of Credit Facility [Line Items] | |
Basis spread on variable rate | 2% |
Alternative Base Rate Spread | ≤ 3.00x | |
Line of Credit Facility [Line Items] | |
Basis spread on variable rate | 1.75% |
Secured Overnight Financing Rate (SOFR) | > 3.50x | |
Line of Credit Facility [Line Items] | |
Basis spread on variable rate | 3.25% |
Secured Overnight Financing Rate (SOFR) | > 3.00x but ≤ 3.50x | |
Line of Credit Facility [Line Items] | |
Basis spread on variable rate | 3% |
Secured Overnight Financing Rate (SOFR) | ≤ 3.00x | |
Line of Credit Facility [Line Items] | |
Basis spread on variable rate | 2.75% |
CREDIT FACILITIES AND NOTES _11
CREDIT FACILITIES AND NOTES PAYABLE - Recent Amendments to Prior Credit Facilities (Details) - USD ($) | Oct. 07, 2022 | Apr. 23, 2021 | Aug. 31, 2018 |
Barclays | Medium-term Notes | |||
Line of Credit Facility [Line Items] | |||
Total credit facilities outstanding | $ 725,000,000 | ||
Truist | Medium-term Notes | |||
Line of Credit Facility [Line Items] | |||
Total credit facilities outstanding | $ 150,000,000 | ||
Debt instrument, face amount | $ 60,000,000 | ||
Revolving Credit Facility | Truist | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Credit facilities available | $ 30,000,000 | ||
Revolving Credit Facility | First Lien Credit Agreement Eighth Amendment | Barclays | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Credit facilities available | $ 195,000,000 | ||
Revolving Credit Facility | First Lien Credit Agreement Eighth Amendment | Truist | Line of Credit | |||
Line of Credit Facility [Line Items] | |||
Credit facilities available | $ 50,000,000 |
LEASES (Details)
LEASES (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Lessee, Lease, Description [Line Items] | |
Operating lease not yet commenced | $ 4.6 |
Minimum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term of contract | 5 years |
Operating lease, renewal term | 10 years |
Lease term of contract | 5 years |
Operating lease, lease not yet commenced, term of contract | 1 year |
Maximum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term of contract | 15 years |
Operating lease, renewal term | 35 years |
Lease term of contract | 8 years |
Operating lease, lease not yet commenced, term of contract | 15 years |
LEASES - Lease Cost (Details)
LEASES - Lease Cost (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Leases [Abstract] | |||
Operating lease cost | $ 106,954 | $ 107,475 | $ 121,578 |
Finance lease cost: | |||
Depreciation of leased equipment | 1,204 | 2,896 | 3,068 |
Interest on lease liabilities | 0 | 0 | 46 |
Total finance lease cost | 1,204 | $ 2,896 | 3,114 |
Lease abandonment charges | $ 2,700 | $ 12,600 |
LEASES - Supplemental Cash Flow
LEASES - Supplemental Cash Flows (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Cash paid for amounts included in the measurement of lease liabilities: | |||
Operating cash flows from operating leases | $ 101,516 | $ 108,004 | $ 110,288 |
Operating cash flows from financing leases | 0 | 0 | 46 |
Financing cash flows from financing leases | 0 | 0 | 3,304 |
Right-of-use & Equipment assets obtained in exchange for lease obligations: | |||
Operating leases | $ 55,852 | $ 88,080 | $ 186,695 |
LEASES - Supplemental Balance S
LEASES - Supplemental Balance Sheet (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Operating Leases | ||
Operating lease right-of-use assets | $ 596,032 | $ 603,524 |
Current portion of operating lease liability | 55,981 | 57,607 |
Long-term operating lease liability | 605,097 | 604,117 |
Total operating lease liabilities | 661,078 | 661,724 |
Finance Leases | ||
Equipment at cost | $ 13,971 | $ 13,971 |
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] | Property Plant and Equipment Net Including Right of Use Assets | Property Plant and Equipment Net Including Right of Use Assets |
Accumulated depreciation | $ (13,374) | $ (12,171) |
Equipment, net | $ 597 | $ 1,801 |
Weighted Average Remaining Lease Term | ||
Operating leases - years | 10 years 7 months 6 days | 10 years 10 months 24 days |
Weighted Average Discount Rate | ||
Operating leases | 6.70% | 6.40% |
LEASES - Maturities of Operatin
LEASES - Maturities of Operating and Finance Lease (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Operating Leases | ||
2024 | $ 97,603 | |
2025 | 92,092 | |
2026 | 91,400 | |
2027 | 88,977 | |
2028 | 85,633 | |
Thereafter | 482,594 | |
Total Lease Payments | 938,299 | |
Less imputed interest | (277,221) | |
Total | $ 661,078 | $ 661,724 |
INCOME TAXES - Income (Loss) Be
INCOME TAXES - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
US Domestic | $ 60,374 | $ 59,529 | $ 58,806 |
Foreign | (21,564) | (16,560) | 73 |
Income (loss) before income taxes | $ 38,810 | $ 42,969 | $ 58,879 |
INCOME TAXES - Income Tax Expen
INCOME TAXES - Income Tax Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Federal current tax | $ 0 | $ 0 | $ 0 |
State current tax | 3,442 | 371 | (2,191) |
Foreign current tax | 638 | 87 | 18 |
Other current tax | 0 | 0 | 0 |
Federal deferred tax | 8,960 | 6,470 | 9,831 |
State deferred tax | (2,724) | 5,863 | 6,902 |
Foreign deferred tax | (1,843) | (3,430) | 0 |
Currency translation | 0 | 0 | 0 |
Income tax expense | $ 8,473 | $ 9,361 | $ 14,560 |
INCOME TAXES - Reconciliation o
INCOME TAXES - Reconciliation of the Statutory U.S. Federal Rate and Effective Rates (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Federal tax | $ 8,150 | $ 9,023 | $ 12,365 |
State franchise tax, net of federal benefit | 3,730 | 595 | 4,198 |
Other Non deductible expenses | 196 | 305 | (93) |
Officer Compensation | 1,199 | 759 | 291 |
Noncontrolling interests in partnerships | (5,752) | (4,821) | (4,114) |
Changes in valuation allowance | (2,569) | 6,124 | (249) |
Return to provision | 5,987 | 234 | (2,530) |
Deferred true-ups and other | 483 | (1,451) | 5,009 |
Foreign rate differential | (1,083) | (737) | 4 |
Uncertain tax provisions | (884) | (749) | (321) |
Tax rate adjustment | (984) | 0 | 0 |
Other differences | 0 | 79 | 0 |
Income tax expense | $ 8,473 | $ 9,361 | $ 14,560 |
INCOME TAXES - Deferred Tax Ass
INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Net operating losses | $ 43,247 | $ 68,124 |
Accrued expenses | 4,432 | 3,941 |
Operating lease liability | 136,097 | 142,347 |
Equity compensation | 4,179 | 4,387 |
Allowance for doubtful accounts | 2,198 | 3,071 |
Other | 15,755 | 6,541 |
Valuation allowance | (9,688) | (12,095) |
Total Deferred Tax Assets | 196,220 | 216,316 |
Deferred tax liabilities: | ||
Property and equipment | (7,851) | (9,214) |
Goodwill | (42,419) | (38,820) |
Intangibles | (15,578) | (18,640) |
Operating lease right-of-use asset | (122,840) | (129,802) |
Outside basis difference | (18,547) | (20,015) |
Other | (4,761) | (9,081) |
Total Deferred Tax Liabilities | (211,996) | (225,572) |
Net Deferred Tax Liability | $ (15,776) | $ (9,256) |
INCOME TAXES - Additional Infor
INCOME TAXES - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Loss Carryforwards [Line Items] | ||||
Net operating losses | $ 43,247 | $ 68,124 | ||
Foreign operating loss carryforwards, not subject to expiration | 45,800 | |||
Deferred tax assets, tax benefit may not be realized | 196,200 | |||
Deferred tax liabilities goodwill | 42,419 | 38,820 | ||
Unrecognized tax benefits | 3,082 | $ 4,144 | $ 5,088 | $ 5,484 |
Unrecognized tax benefits, tax impact if recognized | 2,500 | |||
Unrecognized tax benefits, income tax penalties and interest accrued during period | (47) | |||
Unrecognized tax benefits, income tax penalties and interest accrued | 400 | |||
Domestic Tax Authority | ||||
Operating Loss Carryforwards [Line Items] | ||||
Net operating losses | 128,900 | |||
Operating loss carryforwards, subject to expiration | 63,900 | |||
Operating loss carryforwards, not subject to expiration | 65,000 | |||
State and Local Jurisdiction | ||||
Operating Loss Carryforwards [Line Items] | ||||
Net operating loss carryforward | 145,300 | |||
Raven Holdings | Domestic Tax Authority | ||||
Operating Loss Carryforwards [Line Items] | ||||
Operating loss carryforwards, subject to expiration | $ 24,900 |
INCOME TAXES - Unrecognized Tax
INCOME TAXES - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Unrecognized tax benefit, Balance at beginning of year | $ 4,144 | $ 5,088 | $ 5,484 |
Increases related to prior year tax positions | 54 | 55 | 317 |
Increases related to current year tax positions | 62 | 0 | 0 |
Expiration of the statute of limitations for the assessment of taxes | (1,180) | (999) | (713) |
Increase related to change in rate | 2 | 0 | 0 |
Unrecognized tax benefit, Balance at end of year | $ 3,082 | $ 4,144 | $ 5,088 |
STOCK-BASED COMPENSATION (Detai
STOCK-BASED COMPENSATION (Details) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||
Jan. 31, 2023 tranche $ / shares shares | Jan. 31, 2022 tranche shares | Jun. 30, 2020 $ / shares shares | Dec. 31, 2023 USD ($) incentivePlan shares | Dec. 31, 2022 shares | Apr. 15, 2021 shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of plans | incentivePlan | 1 | |||||
Shares authorized (in shares) | 20,100,000 | |||||
Restated Plan | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards (in shares) | 4,069,349 | |||||
DeepHealth, Inc. | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Options granted (in dollars per share) | $ / shares | $ 16.93 | |||||
Nonvested restricted stock subject to service vesting | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Stock-based compensation (in shares) | 8,718,185 | |||||
RSA's unvested (in shares) | 537,358 | |||||
Granted (in shares) | 825,255 | |||||
Future Service | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Granted (in shares) | 50,765 | |||||
Issuance of stock upon exercise of options | $ | $ 1.3 | |||||
Shares issuable upon the exercise of stock options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Unrecognized stock-based compensation expense | $ | $ 1.4 | |||||
Unrecognized expense weighted average period | 1 year 2 months 23 days | |||||
Shares issuable upon the exercise of stock options | DeepHealth, Inc. | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Granted (in shares) | 412,434 | |||||
Performance Based Stock Options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 3 years | 3 years | ||||
Granted (in shares) | 235,227 | 111,925 | ||||
Number of vesting traches | tranche | 3 | 3 | ||||
Performance Based Stock Options | Director | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Shares issued (in shares) | 27,981 | |||||
Shares issued per share (in dollars per share) | $ / shares | $ 29.44 | |||||
LTIPs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
RSA's unvested (in shares) | 224,725 | 169,471 | ||||
Granted (in shares) | 216,460 | |||||
Performance Based Stock Units | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 3 years | |||||
Granted (in shares) | 60,685 | 25,683 | ||||
Number of vesting traches | tranche | 2 | |||||
Number of shares expected to vest (in shares) | 121,370 | |||||
Performance Based Stock Units | Director | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Shares issued (in shares) | 12,843 | |||||
Shares issued per share (in dollars per share) | $ / shares | $ 29.44 | |||||
Minimum | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 1 year | |||||
Share-based payment award, expiration period | 5 years | |||||
Minimum | Restated Plan | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 3 years | |||||
Share-based payment award, expiration period | 5 years | |||||
Minimum | Performance Based Stock Options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Award vesting rights, percentage | 0% | |||||
Number of shares available in grant (in shares) | 0 | |||||
Minimum | LTIPs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 2 years | |||||
Minimum | Performance Based Stock Units | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Award vesting rights, percentage | 0% | 0% | ||||
Maximum | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 5 years | |||||
Share-based payment award, expiration period | 10 years | |||||
Maximum | Restated Plan | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 5 years | |||||
Share-based payment award, expiration period | 10 years | |||||
Maximum | Performance Based Stock Options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of shares available in grant (in shares) | 235,227 | 111,925 | ||||
Maximum | LTIPs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based payment award, award vesting period | 4 years | |||||
Maximum | Performance Based Stock Units | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Award vesting rights, percentage | 200% | 200% |
STOCK-BASED COMPENSATION - Outs
STOCK-BASED COMPENSATION - Outstanding Options and Warrants (Details) $ / shares in Units, $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) $ / shares shares | |
Shares | |
Beginning Balance (in shares) | shares | 678,914 |
Exercised (in shares) | shares | (12,723) |
Ending Balance (in shares) | shares | 911,411 |
Exercisable at the end (in shares) | shares | 668,809 |
Weighted Average Exercise price Per Common Share | |
Beginning Balance (in dollars per share) | $ / shares | $ 15.72 |
Exercised (in dollars per share) | $ / shares | 11.11 |
Ending Balance (in dollars per share) | $ / shares | 16.60 |
Exercisable at the end (in dollars per share) | $ / shares | $ 14.75 |
Weighted Average Remaining Contractual Life(in years) | |
Balance at end of period | 6 years 2 months 19 days |
Exercisable at the end | 5 years 2 months 26 days |
Aggregate Intrinsic Value | |
Aggregate value outstanding | $ | $ 16,561,659 |
Aggregate value exercisable | $ | $ 13,387,921 |
Equity Option | |
Shares | |
Granted (in shares) | shares | 261,220 |
Canceled, forfeited or expired (in shares) | shares | (16,000) |
Weighted Average Exercise price Per Common Share | |
Granted (in dollars per share) | $ / shares | $ 18.64 |
Canceled, forfeited or expired (in dollars per share) | $ / shares | $ 17.06 |
DeepHealth, Inc. | |
Shares | |
Beginning Balance (in shares) | shares | 116,982 |
Exercised (in shares) | shares | (37,909) |
Ending Balance (in shares) | shares | 79,073 |
Exercisable at the end (in shares) | shares | 76,612 |
Weighted Average Exercise price Per Common Share | |
Beginning Balance (in dollars per share) | $ / shares | |
Exercised (in dollars per share) | $ / shares | 0 |
Ending Balance (in dollars per share) | $ / shares | 0 |
Exercisable at the end (in dollars per share) | $ / shares | $ 0 |
Weighted Average Remaining Contractual Life(in years) | |
Balance at end of period | 5 years 9 months |
Exercisable at the end | 5 years 9 months |
Aggregate Intrinsic Value | |
Aggregate value outstanding | $ | $ 2,749,368 |
Aggregate value exercisable | $ | $ 2,663,803 |
STOCK-BASED COMPENSATION - RSU'
STOCK-BASED COMPENSATION - RSU's and LTIPs (Details) | 1 Months Ended | 12 Months Ended | ||
Jan. 31, 2023 tranche $ / shares shares | Jan. 31, 2022 tranche shares | Dec. 31, 2023 $ / shares shares | Dec. 31, 2022 shares | |
Minimum | ||||
Weighted-Average Fair Value | ||||
Share-based payment award, award vesting period | 1 year | |||
Maximum | ||||
Weighted-Average Fair Value | ||||
Share-based payment award, award vesting period | 5 years | |||
Restricted Stock | ||||
RSA's | ||||
Outstanding, beginning balance (in shares) | 536,767 | 536,767 | ||
Granted (in shares) | 825,255 | |||
Vested (in shares) | (785,656) | |||
Forfeited (in shares) | (39,008) | |||
Outstanding, ending balance (in shares) | 537,358 | |||
Weighted-Average Remaining Contractual Term (Years) | 10 months 24 days | |||
Weighted-Average Fair Value | ||||
Beginning balance (in dollars per share) | $ / shares | $ 23.84 | $ 23.84 | ||
Granted (in dollars per share) | $ / shares | 21.31 | |||
Vested (in dollars per share) | $ / shares | 22.12 | |||
Forfeited (in dollars per share) | $ / shares | 18.31 | |||
Ending balance (in dollars per share) | $ / shares | $ 22.99 | |||
RSA's unvested (in shares) | 537,358 | |||
Performance Based Stock Units | ||||
RSA's | ||||
Granted (in shares) | 60,685 | 25,683 | ||
Weighted-Average Fair Value | ||||
Number of vesting traches | tranche | 2 | |||
Share-based payment award, award vesting period | 3 years | |||
Performance Based Stock Units | Minimum | ||||
Weighted-Average Fair Value | ||||
Award vesting rights, percentage | 0% | 0% | ||
Performance Based Stock Units | Maximum | ||||
Weighted-Average Fair Value | ||||
Award vesting rights, percentage | 200% | 200% | ||
Performance Based Stock Options | ||||
Weighted-Average Fair Value | ||||
Number of vesting traches | tranche | 3 | 3 | ||
Share-based payment award, award vesting period | 3 years | 3 years | ||
Performance Based Stock Options | Minimum | ||||
Weighted-Average Fair Value | ||||
Award vesting rights, percentage | 0% | |||
Number of shares available in grant (in shares) | 0 | |||
Performance Based Stock Options | Maximum | ||||
Weighted-Average Fair Value | ||||
Number of shares available in grant (in shares) | 235,227 | 111,925 | ||
LTIPs | ||||
RSA's | ||||
Granted (in shares) | 216,460 | |||
Forfeited or Canceled (in shares) | (94,897) | |||
Weighted-Average Remaining Contractual Term (Years) | 2 years 8 months 23 days | |||
Weighted-Average Fair Value | ||||
Beginning balance (in dollars per share) | $ / shares | $ 19.56 | $ 19.56 | ||
Granted (in dollars per share) | $ / shares | 20.24 | |||
Forfeited or Canceled (in dollars per share) | $ / shares | 19.82 | |||
Ending balance (in dollars per share) | $ / shares | $ 20.08 | |||
RSA's unvested (in shares) | 224,725 | 169,471 | ||
LTIPs | Minimum | ||||
Weighted-Average Fair Value | ||||
Share-based payment award, award vesting period | 2 years | |||
LTIPs | Maximum | ||||
Weighted-Average Fair Value | ||||
Share-based payment award, award vesting period | 4 years | |||
AI Long Term Incentive Plan shares | ||||
RSA's | ||||
Vested (in shares) | (66,309) | |||
Weighted-Average Fair Value | ||||
Vested (in dollars per share) | $ / shares | $ 19.62 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions | Feb. 01, 2024 | Feb. 16, 2023 |
Houston Medical Imaging, LLC | ||
Subsequent Event [Line Items] | ||
Consideration transferred | $ 29 | |
Antelope Valley Outpatient Imaging Center, LLC | Subsequent Event | ||
Subsequent Event [Line Items] | ||
Consideration transferred | $ 3.5 |